WO1998024503A1 - System for stent placement in ostial lesions - Google Patents
System for stent placement in ostial lesions Download PDFInfo
- Publication number
- WO1998024503A1 WO1998024503A1 PCT/US1997/023165 US9723165W WO9824503A1 WO 1998024503 A1 WO1998024503 A1 WO 1998024503A1 US 9723165 W US9723165 W US 9723165W WO 9824503 A1 WO9824503 A1 WO 9824503A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stent
- ostial
- segment
- shuttle
- catheter
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
- A61F2/958—Inflatable balloons for placing stents or stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/01—Filters implantable into blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2002/821—Ostial stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0096—Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers
- A61F2250/0098—Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers radio-opaque, e.g. radio-opaque markers
Definitions
- the present invention relates to a stent delivery system to be used for stent placement in an ostial lesion.
- the stent delivery system of the invention comprises a stent delivery assembly having a break segment which changes configuration to facilitate localization of the target ostium.
- PTCA percutaneous transluminal coronary angioplasty
- PTCA has, however, two major shortcomings: first, in 3-5% of patients treated with PTCA, the treated coronary artery re-occludes within the first 24-48 hours after the procedure, despite the use of anticoagulant drugs to deter the reformation of the occlusion (called “abrupt closure”); second, in 30-50% of patients treated with PTCA, the subsequent healing process in the treated coronary artery is associated with sufficient recoil, scarring and/or proliferation of smooth muscle cells to cause re- occlusion of the artery (called "restenosis"). In hopes of preventing abrupt closure and restenosis, coronary artery stents were developed (Topol, 1994, N. Engl. J. Med. 331:539-541).
- Such stents are tubular devices which provide structural support for maintaining an open vessel. Recently, the placement of such stents has been found to be associated with better angiographic and clinical outcomes than PTCA (Serruys et al., 1994, N. Engl. J. Med. 331 :489-495; Fischman et al., 1994, N. Engl. J. Med. 331 :496-501), including a lower rate of restenosis.
- Procedures used for stent deployment in a vessel generally involve the introduction of a stent, in a contracted condition, into a vessel and the optimal localization of the stent relative to the intended implantation or target site, followed by the expansion of the stent such that it is locked in the desired position in apposition to the vessel wall.
- Certain stents require an ancillary means for expansion.
- a stent may be fitted over a collapsed angioplasty balloon, which is then introduced into the vessel and inflated, thereby expanding the stent and deploying it in the desired location.
- Such stents are referred to as "non-self-expanding stents”.
- stents are capable of expanding when released from the contracted condition (similar to the release of a compressed spring); such stents are referred to as "self-expanding stents".
- the optimal conventional strategy for implantation of non-self- expanding stents typically incorporates three distinct steps. First, where an obstruction narrows a vessel to an extent which precludes introduction of the stent delivery system, an adequate channel for passage of the balloon-stent assembly is created by inflating a balloon not carrying a stent within the stenosed region (hereafter referred to as pre-dilatation).
- the balloon-stent assembly is advanced into the target vessel, the collapsed stent is localized and optimally positioned relative to the intended implantation site in the stenosis, and the stent is expanded by inflating the carrier balloon, so as to achieve contact between the stent and the walls of the vessel (deployment).
- the balloon used for deployment is optimally, when inflated, of the same or slightly greater diameter than the vessel adjacent to the treatment site and of the same or greater length than the stent.
- the balloon used for post-dilatation is optimally of the same length or shorter than the stent. While the first and third of these three steps may occasionally be omitted, they are recommended for most stent placement applications. For best results, the choice of balloon optimal for one of the foregoing three steps is typically not optimal for the other steps. However, when multiple balloons are used, the duration, technical difficulty and cost of the procedure increase.
- the ostium of a vessel is located at the point of origin of the vessel.
- a vessel branches off from a larger parent conduit vessel.
- the aorta gives rise to the coronary arteries; the origin of each coronary artery as it branches from the aorta is referred to as an ostium.
- a lesion e.g., an atherosclerotic plaque located at the ostium of a vessel is referred to as an "ostial lesion".
- the main challenges in stenting ostial lesions in native coronary arteries, bypass grafts, renal arteries, subclavian or innominate artiers, carotid arteries and any other vessels arising from the aorta are (i) the difficulty involved in precisely localizing the ostium itself angiographically during stent delivery and implantation; (ii) the unpredictable interactions between the guiding catheter and the stent delivery system; and (iii) optimal placement of the stent covering the ostium of the target vessel without significant length of the stent protruding into the parent vessel.
- the guiding catheter is optimally positioned outside the ostium but in sufficient proximity to opacity the adjacent aorta and thereby localize the target ostium.
- the guiding catheter must be maintained at a sufficient distance from the ostium to avoid dislodging or damaging the stent. Maintaining proper position of the guiding catheter and stent assembly may be further complicated by forceful blood flow through the parent vessel, e.g., the aorta.
- the present invention relates to a stent delivery system to be used in the placement of one or more stents in an ostial lesion in a patient in need of such treatment.
- the stent delivery system of the invention comprises a stent delivery assembly having a distally located deployment segment, wherein the deployment segment comprises a break segment which has an alterable configuration, as well as a stent-bearing segment.
- the break segment may be introduced into the patient in a first configuration.
- the configuration of the break segment may be altered to assume a second, expanded, configuration which may be lodged against the wall of the parent conduit vessel, thereby localizing the ostium of the target vessel containing the lesion and ensuring that the stent(s) is(are) in the proper position for deployment.
- the dimension of the break segment in its expanded configuration orthogonal to the long axis of the target vessel is greater than the diameter of the ostium of the target vessel.
- One or more stents mounted, in a contracted configuration, on the deployment segment may then be deployed by expanding the deployment segment.
- the configuration of the break segment may then be reversed to assume the first (unexpanded) configuration, and the entire assembly may be withdrawn from the patient.
- the ostial stent delivery system of the invention may be used to avoid the complications associated with conventional methods of ostial stent placement by enabling accurate localization of the target ostium while protecting the stent from being damaged or dislodged by, for example, a guiding catheter.
- FIGURE 1 Deployment segment of ostial stent delivery system in (A) deactivated, and (b) activated, configuration.
- FIGURE 2 Deployment segment of ostial shuttle showing forward break segment in (A) deactivated, and (B) activated, configuration.
- FIGURE 3 Deployment segment of ostial shuttle wherein mechanism of activation of forward break segment is a balloon in (A) deactivated, and (b) activated, configuration.
- FIGURE 4 Deployment segment of ostial shuttle wherein mechanism of activation of forward break segment is a nitinol wire in (A) deactivated, and (B) activated, configuration.
- FIGURE 5 Deployment segment of ostial shuttle wherein mechanism of activation of forward break segment is a pair of articulated wires in (A) deactivated, and (B) activated, configuration.
- FIGURE 6 Introduction of ostial shuttle, via a guiding catheter passed over a guide wire, into the proximity of the target ostial lesion.
- FIGURE 7 Pre-dilatation of ostial lesion by inflation of a balloon comprised in a catheter passed over the guide wire.
- FIGURE 8 Advancement of the balloon distally in the target vessel, past the ostial lesion.
- FIGURE 9 Advancement of the ostial shuttle, via the guiding catheter, over the shaft of the balloon catheter, into the target vessel.
- FIGURE 10 Withdrawal of the guiding catheter out of the target vessel and into the aorta.
- FIGURE 11 Partial withdrawal of the ostial shuttle, so that the distal portion of the ostial deployment segment remains in the target vessel but the proximal end of the ostial deployment segment is in the aorta.
- FIGURE 12. Activation of the forward break segment of the ostial deployment segment.
- FIGURE 13 Advancement of the ostial deployment segment until the forward break segment comes to a stop against the aortic wall.
- FIGURE 14 Retraction of balloon into the stent deployment segment of the ostial shuttle and stent deployment by expansion of balloon in ostial deployment segment.
- FIGURE 15 Deactivation of forward break segment prior to withdrawal of assembly from patient.
- FIGURE 16 Release of a pharmaceutical substance upon expansion of deployment segment.
- FIGURE 17 Deployment segment of ostial stent delivery system with rear break segment in (A) deactivated, and (B) activated, configuration.
- FIGURE 18 Deployment segment of ostial shuttle showing rear break segment in (A) deactivated, and (b) activated, configuration.
- Ostial stent delivery systems of the invention share the common feature of an ostial deployment segment having a reversibly expandable break segment located adjacent to the stent-bearing region.
- the break segment when activated to an expanded configuration, allows the deployment segment to be stably and accurately positioned at the ostium of a target vessel to be stented.
- FIGURE 1 depicts a deployment segment (2) of an ostial stent delivery system (1) showing forward break segment (3), optimally positioned immediately adjacent to the stent-carrying segment, in (A) deactivated (3 A) and (B) activated (3B) configuration.
- the ostial stent delivery system (1) includes a stent (6) crimped on a balloon (11) (prior to deployment) distal to the forward break segment.
- FIGURE 2 depicts a deployment segment (2) of an ostial shuttle stent delivery system (1) showing forward break segment (3) in (A) deactivated (3C), and (B) activated (3D), configurations.
- the ostial shuttle stent delivery system (1) includes a tubular catheter (4; distal region only shown), having, at its distal end, a deployment segment (2) comprising, proximal to distal, a forward break segment (3), and an expandable segment (5) on which a stent (6) is mounted.
- FIGURE 3 depicts a deployment segment (2) of an ostial shuttle stent delivery system ( 1 ), as in FIGURE 1 , wherein the mechanism of activation of the forward break segment (3) is a balloon, in (A) deactivated (3E) and (B) activated (3F) configurations.
- FIGURE 4 depicts a deployment segment (2) of an ostial shuttle stent delivery system (1), as in FIGURE 2, wherein the mechanism of activation of the forward break segment (3) is a nitinol wire loop (7), showing the forward break segment in (A) deactivated (3G), and (B) activated (3H), configurations.
- FIGURE 5 depicts a deployment segment (2) of an ostial shuttle stent delivery system (1), as in FIGURE 2 wherein the mechanism of activation of the forward break segment (3) is a pair of articulated wires (8) having articulations (20) and attached to a longitudinally placed retention wire (21), showing the forward break segment in (A) deactivated (31), and (B) activated (3J), configurations.
- the mechanism of activation of the forward break segment (3) is a pair of articulated wires (8) having articulations (20) and attached to a longitudinally placed retention wire (21), showing the forward break segment in (A) deactivated (31), and (B) activated (3J), configurations.
- FIGURES 6-15 depict, schematically, a method which may be used for stent placement in an ostial lesion (9) of a target artery (10) branching off a parent conduit vessel (15).
- the stent (6) is deployed by expansion of the stent-bearing portion (5) of the deployment segment of an ostial shuttle (2) by a balloon (11) comprised in a balloon catheter (12).
- an expandable, stent-bearing segment (5 A) of the deployment segment (2) is flanked by less-expandable segments (13).
- FIGURE 6 a guiding catheter (16), carrying an ostial shuttle delivery system (1) and, within the tubular catheter of the shuttle (4), a balloon catheter (12), has been introduced into the proximity of the ostial lesion (9).
- a guide wire (14) has been passed, via the guiding catheter (16), through the parent conduit vessel (15) into an artery (10) having an ostial lesion (9).
- FIGURE 7 depicts pre-dilatation of the ostial lesion (9).
- the balloon catheter (12) has been advanced over the guide wire (14) so that the balloon is located within the ostial lesion (9), and the balloon is inflated (11 A).
- the balloon (11) has been deflated and the balloon catheter (12) has been advanced over the guide wire (14) into the artery (10) distal to the pre-dilated ostial lesion (9).
- the ostial shuttle (1) has been advanced, out of the guiding catheter (16), over the shaft (17) of the balloon catheter (12), into the target artery (10) distal to the ostial lesion (9).
- the guiding catheter (16) has been withdrawn out of the target artery (10) and into the parent conduit vessel (15).
- the distal end of the ostial shuttle (IB) remains in the target artery (10).
- the ostial shuttle (1) has been partially withdrawn, so that the distal portion of the ostial deployment segment (2) remains in the target artery but the proximal end of the ostial deployment segment is in the parent conduit vessel (15).
- FIGURE 12 depicts activation of the forward break segment (3) of the ostial deployment segment (2). Activation is achieved, in this specific nonlimiting example, by inflating a balloon comprised in the forward break segment into activated configuration (3F).
- stent deployment has been achieved by withdrawing the balloon (11) into the ostial deployment segment (2), and inflating the balloon (11 A), thereby expanding the expandable stent-bearing portion (5 A) and expanding and deploying the stent (6A).
- the activated forward break segment (3F) prevents the guiding catheter (16), positioned in the parent conduit vessel (15), from damaging or dislodging the expanded stent (6A).
- the forward break segment has been deactivated (3E) prior to withdrawal of the guide wire (14), balloon catheter (12), guiding catheter (16), and ostial shuttle stent delivery system (1) from the patient.
- FIGURE 16 illustrates, in a magnified view, the release of a pharmaceutical substance (18) represented by triangles, released by the rupture of thin-walled vesicles (19), when the deployment segment (shown in relaxed conformation in A) is expanded (B).
- FIGURE 17 depicts a deployment segment (2) of an ostial stent delivery system (1) showing a osterior break segment (22) in (A) deactivated (22 A) and (B) activated (22B) configuration.
- FIGURE 18 depicts a deployment segment (2) of an ostial shuttle stent delivery system (1) showing a posterior break segment (22) in (A) deactivated (22C) and (B) activated (22D) configuration.
- the present invention may be used in vessels or similar conduits wherein a "parent conduit” vessel gives rise to a branch which is a smaller vessel containing an ostial lesion; this smaller vessel is referred to herein as the "target" vessel.
- the branching of the parent conduit vessel to give rise to the target vessel has a structure which resembles the origin of the coronary arteries from the aorta.
- the invention may be applied to vessels such as but not limited to, bypass grafts, renal arteries, subclavian or innominate arteries, carotid arteries (or any other vessels arising from the aorta), shunts, bronchial branches, ureters, fallopian tubes, cystic and pancreatic ducts.
- the invention may also be applied to structures wherein a target vessel containing an ostial lesion opens into a larger space, for example, but not by way of limitation, the urethra (containing an ostial lesion) opening into the bladder.
- STENTS Stents which may be delivered according to the invention include any vascular or non-vascular stent intended to be placed within a blood vessel (e.g. an artery or vein, including but not limited to a coronary artery, a carotid artery, the aorta and vena cava) or similar structure.
- Vascular stents which may be used according to the invention include but are not limited to Palmaz-Schatz, Gianturco-Roubin, Cook, AVE, Strecker, Wiktor, Wallsten and Cordis stents.
- Stents which may be delivered according to the invention are not limited as to the design, material, length or thickness of the stent, and multiple contiguous or non-contiguous stents may be delivered.
- the break segment of the invention is physically associated with the device on which the stent to be deployed is mounted, so that the break segment, in activated conformation, can be lodged in the ostium, thereby stably retaining the stent in the desired position for deployment.
- the break segment may be located proximal to (a "forward break segment"), or alternatively, distal to (a "posterior break segment"), the mounted stent.
- the stent is positioned immediately adjacent to the break segment.
- the break segment may be comprised in a shuttle ostial deployment system, as described in the following section 5.3.
- the break segment may be comprised in any other device used for stent deployment known in the art.
- the break segment may be comprised in the balloon catheter so as to satisfy the functional criteria set forth above.
- FIGURE 1 depicts a balloon catheter wherein a stent is crimped onto the balloon, comprising a forward break segment in activated and deactivated configurations.
- FIGURE 17 depicts a similar balloon catheter/stent assembly comprising a posterior break segment in activated and deactivated configurations.
- the break segment consists of a balloon which may be inflated to create the activated configuration and deflated so as to create the deactivated configuration.
- FIGURES 2-15 and 18 relate to the use of break segments in an ostial shuttle stent delivery system (see Section 5.3, infra.).
- the break segment may be fabricated from various materials, depending upon its means on activation. If the means for achieving activation is a separate activating component, such as a nitinol wire or articulated wire, the break segment may be fabricated of a base material which allows the reversible expansion of the activating component, even if the base material is not, itself, activated. In order to permit reversible expansion of such an activating component, the base material should be sufficiently expandable and elastic to permit assumption of the activated configuration and then reversion to the deactivated configuration. For example, but not by way of limitation, the base material of the break segment may be polyethylene or nylon.
- the minimum inner radial diameter of the forward break segment has the same size constraints as the shuttle catheter as a whole; namely, it must be large enough to accommodate devices that are to be passed through it.
- the inner diameter should be large enough to accommodate the passage of a guide wire and the ancillary means of expansion (e.g., a balloon catheter); in nonlimiting embodiments, the inner diameter may be in the range of from 0.8 to 1.6 millimeters, and preferably from 0.9 to 1.3 millimeters.
- the maximum outer diameter of the break segment, in deactivated configuration should also conform to its intended function.
- the outer diameter of the break segment, in deactivated configuration should be small enough to allow passage into a guiding catheter, and small enough to be safely passed into a coronary artery; in nonlimiting embodiments, the outer radial diameter may be in the range of from 1.0 to 2.0 millimeters, and preferably from 1.3 to 1.7 millimeters.
- the break segment When the break segment is activated (expanded), its outer radial diameter may preferably (and not by way of limitation) be increased by 100-300 percent, and more preferably by 200 percent, in order to safely exceed the diameter of the ostium of the target vessel.
- the outer diameter of the break segment, in activated configuration may be in the range from 2.0 to 6.0 millimeters and preferably from 3.0 to 5.0 millimeters.
- the break segment comprises a balloon which may be inflated to achieve an activated configuration and deflated to achieve a deactivated configuration.
- a break segment may be comprised within a balloon catheter upon which a stent may be mounted prior to deployment, as depicted in Figures 1 and 17.
- the break segment may be activated by, for example but not by way of limitation, inflation using a separate means (e.g., a separate air conduit) from that used to inflate of the balloon catheter.
- a separate means e.g., a separate air conduit
- such a break segment may be comprised in a shuttle stent delivery system, as illustrated in Figures 3 and 6-15.
- the activating component is a nitinol wire comprised in the break segment.
- the nitinol wire is configured such that, upon passage of current through the nitinol wire, the diameter of the break segment expands.
- the nitinol wire may be configured in a loop (see, for example, FIGURE 4) or coil positioned such that the central axis of the loop or coil is parallel with, or coincident with, the central axis of the break segment. Accordingly, the inner diameter of the loop or coil has the same minimum size constraints as the stent placement devise employed.
- the nitinol wire may be embedded within an elastic base material, as described above.
- the nitinol wire may on activated configuration, expand freely from the stent delivery system and in deactivated configuration, may return to its original dimensions.
- the ostial shuttle stent delivery system comprises a means for activating the nitinol wire by passing a current through the nitinol wire.
- the current may be supplied via a battery.
- the activating component may comprise an articulated wire.
- the articulated wire may be configured such that it may be bent at the articulation to increase the diameter of the forward break segment (for example, see FIGURE 5).
- the articulated wire may be brought into its angular configuration by pushing its proximal end while pulling on its distal end, for example, by a retention wire (see FIGURE 5).
- the articulated wire may be fabricated from stainless steel, titanium, or nitinol. It may preferably have a length of 150 to 300 cm.
- the invention may utilize a shuttle stent delivery system:
- a "shuttle" stent delivery system provides the benefits of an optimal three-step stent placement procedure using multiple balloons but obviates the need for balloon exchanges.
- the system utilizes a tubular stent delivery catheter (herein referred to as a "shuttle") comprising a deployment segment having an expandable portion, onto which a stent may be mounted in a contracted conformation.
- the deployment segment is not expanded by means intrinsic to itself, but rather is expanded by ancillary means, for example, by a balloon catheter separate and distinct from the shuttle. Multiple balloon changes are rendered unnecessary because the structural design of the deployment segment supplies the optimal physical characteristics offered by multiple balloons.
- the shuttle comprises a deployment segment having an expandable portion over which a stent is mounted in contracted condition.
- the stent-bearing expandable portion of the deployment segment is flanked by segments which are not expandable to the same degree as the stent-bearing portion.
- the deployment segment comprises a releasable biological, pharmaceutical, or structural substance.
- a guide wire having a length greater than the balloon catheter, may be introduced into the vessel.
- a shuttle with an expandable stent mechanically or by other means attached onto the deployment segment in contracted condition may be mounted coaxially over the shaft of the balloon catheter outside the patient.
- the shuttle may be designed to be coaxially mounted over the shaft of the balloon catheter over the entire length of the shuttle (hereafter referred to as an "over the catheter” shuttle) or only over a distal segment of the shuttle comprising the deployment segment (hereafter referred to as a "monorail" shuttle).
- the balloon catheter used has a length greater than the shuttle.
- the balloon catheter is designed such that the balloon is reliably and repeatedly capable of advancing in unexpanded (i.e., never inflated) or collapsed (i.e., inflated at least once and then deflated) condition through the entire length of the shuttle and in and out of the distal end of the shuttle.
- the occluded region of the vessel may then be pre-dilated using the balloon catheter. Then, without withdrawing the balloon catheter from the patient, the balloon may be deflated and advanced beyond (distal to) the occlusion, and the shuttle, fitting over the shaft of the balloon catheter, may be positioned such that the stent-bearing deployment segment is positioned within the pre-dilated occluded portion of the vessel. The balloon may then be pulled back into the deployment segment of the shuttle, and expanded to high pressures. Expanding the balloon accomplishes deployment of the stent, and also offers the benefits of post-dilatation.
- the need for a separate, shorter, post-dilatation balloon should be obviated by the relatively non-expandable segments flanking the expandable region of the deployment segment, which protect the vessel adjacent to the stent from damage.
- releasable substances comprised in the deployment segment may be liberated by the expansion of the deployment segment via inflation of the balloon.
- the balloon may be deflated and the stent delivery and balloon catheters may be removed from the patient.
- the shuttle stent delivery system may be used for the placement of either non-self-expanding or self-expanding stents in blood vessels or similar structures.
- the system may be used to deploy multiple stents in a single procedure, and may be used in conjunction with an anti-embolic filter.
- An ostial shuttle stent delivery system is a species of tubular catheter (also referred to as a "shuttle catheter") having a distal and a proximal end, wherein the proximal end may preferably be kept outside of the patient (thereby allowing the operator to adjust the position of the stent during placement) and comprising an ostial deployment segment (used for carrying and deploying the stent or stents) located at the distal end (preferably, within 2-3 cm of the distal end of the shuttle catheter).
- a specific example of the distal end of such a shuttle is depicted in FIGURE 2.
- the present invention relates to an ostial shuttle stent delivery system for delivering a stent in a vessel having an ostial lesion in a patient in need of such treatment, comprising a tubular catheter having, at its distal end, an ostial deployment segment comprising (a) in the proximal region of the ostial deployment segment, a forward break segment capable of reversible expansion; and (b) in the distal region of the deployment segment, an expandable portion onto which a stent is mounted.
- the ostial shuttle stent delivery system may comprise a tubular catheter having, at its distal end, an ostial deployment segment comprising (a) in the proximal region of the ostial deployment segment, an expandable portion onto which the stent is mounted; and (b) in the distal region of the ostial deployment segment, a posterior break segment capable of reversible expansion.
- the shuttle catheter may be fabricated from a variety of materials, including, but not limited to, polyethylene, nylon, and nitinol, which are the preferred materials for the placement of stents in blood vessels.
- the length and radial diameter of the shuttle catheter may vary depending upon the vessel or similar structure into which the stent is to be placed.
- the approximate longitudinal length of the shuttle catheter for placement of a stent into a coronary artery may be in the range of from 80 to 140 centimeters, and preferably from 90 to 125 centimeters
- the outer radial diameter may be in the range of from 1.0 to 2.0 millimeters, and preferably from 1.3 to 1.7 millimeters
- the inner radial diameter may be in the range of from 0.8 to 1.6 millimeters, and preferably from 0.9 to 1.3 millimeters.
- the radial diameters are temporarily expanded in embodiments where stent deployment is effected by an ancillary means of expansion.
- the ostial deployment segment of the shuttle comprises one or more expandable portions, onto which one or more stents may be mounted (e.g., compacted) prior to placement in a patient.
- the stent may be mounted on an expandable segment which, in preferred embodiments of the invention, is flanked by segments (called "flanks") which are not expandable or are less expandable than the expandable portion. These less-expandable flanks protect the vessel walls adjacent to the lesion from damage during stent deployment.
- the length of an expandable portion may be, for example, and not by way of limitation, in the range of from 5 to 35 millimeters, and preferably from 9 to 30 millimeters.
- the expandable portion and flanks may be fabricated of different materials, having different expandabilities.
- the expandable portion may be made of the same material as the remainder of the shuttle, and the flanks may be created by placing two short tubular portions of reinforcing material at the boundaries of the expandable portion, or by other means known in the art.
- Markers for example radiopaque markers such as gold, tantalum or platinum markers may be placed at the distal ends of the stent-bearing region of the shuttle, or at the location of the break segment and/or at the boundaries between an expandable portion and its flanks or between the flanks and the remainder of the shuttle to aid in stent positioning.
- radiopaque markers such as gold, tantalum or platinum markers
- One or more stent(s) may be compacted onto the expandable portion or portions of the ostial deployment segment prior to placement in the patient.
- the stent may simply be crimped onto an expandable portion of the deployment segment.
- the stent may be retained in non-expanded form on the shuttle by a restraining mechanism. For example, constraining sleeves may extend over both edges of the stent, retaining it in place until the sleeves are pulled apart by expansion of the expandable portion of the deployment segment.
- the shuttle may optionally comprise a protective sheath which may cover the stent prior to deployment; such a sheath may be removed by retracting it by pulling on its proximal end, which may be kept outside of the patient at all times.
- biological, pharmaceutical, and/or structural materials may be incorporated into the ostial deployment segment of the ostial shuttle, such that these materials may be released upon expansion of the deployment segment by an ancillary means.
- such materials may be incorporated into thin- walled vacuoles near the surface of the deployment segment closest to the wall of the vessel or similar structure into which the stent is to be placed, such that the vacuoles may rupture, releasing their contents, when the deployment segment is expanded.
- a biodegradable polymer layer with antithrombotic and/or antiproliferative properties may be incorporated into the ostial stent delivery catheter either over the mounted stent or between the stent and the expandable portion of the ostial deployment segment. When the deployment segment and the stent are expanded, this layer may be released from the shuttle while remaining attached to the stent in the treatment site.
- Materials which may be incorporated into the deployment segment include, but are not limited to, anticoagulants such as heparin, hirudin, hirulog, or platelet receptor inhibitors, thrombolytic agents such as tissue plasminogen activator, compounds that deter the proliferation of vascular smooth muscle cells (thereby decreasing the likelihood of restenosis) such as radioactive compounds, anti-CD41 antibodies or antisense oligo- deoxynucleotides, radiopaque materials such as iodine or barium salts, structural materials such as fibrin layers, endothelial cells, segments of veins or arteries or synthetic grafts such as dacron.
- anticoagulants such as heparin, hirudin, hirulog, or platelet receptor inhibitors
- thrombolytic agents such as tissue plasminogen activator
- compounds that deter the proliferation of vascular smooth muscle cells thereby decreasing the likelihood of restenosis
- radioactive compounds such as radioactive compounds, anti-CD41 antibodies or antisense oligo- deoxy
- incorporation of such materials into the deployment segment may decrease or eliminate the need for systemic administration of such agents or other adjunct therapies.
- the need for aggressive systemic anti- coagulation may be decreased, thereby diminishing the likelihood of hemorrhagic complications at the vascular access site.
- the tip of the ostial shuttle catheter may, in nonlimiting embodiments, comprise a means for reversible expansion (such as a nitinol wire) to facilitate withdrawal of the ancillary means of expansion into the shuttle catheter for stent deployment and for removal from the patient.
- a means for reversible expansion such as a nitinol wire
- the ostial shuttle catheter may comprise, at its distal tip, a structure or structures capable of forming one or more antiembolic filters, with fenestrations large enough to permit the passage of blood or other fluid, but small enough to trap debris (such as fragments of thrombus or atherosclerotic plaque) freed during pre-dilatation or stent deployment.
- the filter may be capable of fitting over, for example, a balloon catheter shaft or guidewire, and may be capable of expansion by intrinsic or ancillary means.
- an intrinsic means of expansion would include a filter constructed of a thermal memory alloy such as nitinol, which may be expanded by a weak electrical current.
- a balloon may be used to expand the filter.
- the filter and distal region of the ostial shuttle catheter may desirably be constructed such that the filter may be advanced distal to the obstructed region of the vessel and expanded prior to pre-dilatation and stent deployment.
- the filter itself may preferably be sufficiently flexible, by virtue of the material of which it is made or its construction, to permit pull-back of the entire delivery system following stent deployment, with the filter in its expanded shape.
- an embolic filter is comprised in a separate element, wherein the filter (for example, a coiled structure) is positioned distal to the distal tip of the shuttle catheter, and is connected to a small diameter shaft running through the shuttle catheter and extending its proximal end outside of the patient, to permit manipulation by the operator (e.g. forward advancement, retention, and withdrawal).
- the filter for example, a coiled structure
- such an embolic filter may have an alterable configuration; for example, the filter may be constructed of nitinol, and have a first conformation which is a straight wire. Upon the passage of electrical current, this straight wire may assume a second conformation which is an inverted conical spiral of preset maximal diameter.
- the ostial deployment segment of the shuttle catheter may be placed over the shaft of an ancillary means of expansion, such as a balloon catheter.
- an ancillary means of expansion such as a balloon catheter.
- the shuttle catheter may be coaxial with the ancillary means of expansion over the entire length (termed an "over the catheter shuttle") or over the distal segment of the ostial shuttle catheter comprising the ostial deployment segment (termed a "monorail shuttle").
- the shuttle ostial stent delivery system of the invention provides for an ancillary means of expanding the ostial deployment segment of the shuttle. While means of expansion other than a balloon catheter are envisioned (such as, for example, a nitinol wire, the distal segment of which is made to become a coil of a predetermined diameter when placed within the expandable deployment segment of the shuttle and when a weak electrical current is passed through such a nitinol wire) this ancillary element will be exemplified by and referred to hereafter as a balloon catheter.
- the balloon catheter may be fabricated from a variety of materials, including, but not limited to, polyethylene and nylon, which are the preferred materials for the placement of stents in blood vessels.
- the length and radial diameter of the balloon catheter may vary depending upon the vessel or similar structure into which the stent is to be placed.
- the approximate length of the shaft of a balloon catheter for placement of a stent into a coronary artery may be in the range of from 80 to 140 centimeters, and preferably from 90 to 125 centimeters
- the radial diameter of the shaft portion may be in the range of from 0.8 to 1.6 millimeters, and preferably from 0.9 to 1.3 millimeters.
- the balloon portion of the balloon catheter may desirably be structured such that the balloon is capable of repeatedly and reliably advancing in unexpanded condition as well as in collapsed condition through the entire length of the shuttle, and in and out of the distal ends of the shuttle.
- the balloon may preferably be a non-compliant high-pressure balloon with longer tapered ends and a smaller refolded diameter.
- Such a balloon may have an exaggerated gradual gentle shoulder, wherein the change from the diameter of the balloon shaft adjacent to the balloon membrane (to which the balloon membrane is tethered) to the diameter of the fully expanded balloon takes place over a relatively long distance.
- such a balloon may preferably collapse with its edges re-wrapped snugly on the shaft without heaping up.
- a balloon maintains the diameter of the collapsed balloon (which consists of the collapsed balloon membrane and tapered catheter shaft) smaller than the more proximal shaft of the catheter.
- the balloon in preferably fabricated from polyethylene or nylon.
- the dimensions of the balloon may be as follows.
- the balloon may preferably reach, in an inflated state, a diameter ranging from 2.0 to 5.0 millimeters, and more preferably from 2.5 to 4.5 millimeters, and an internal pressure of from 0 to 20 atmospheres, and more preferably from 4 to 20 atmospheres.
- Such a balloon may preferably have a rated burst pressure of from 12 to 20 atmospheres.
- RESULTS OF STENT PLACEMENT The following is a general description of a method for stent placement in a vessel having an ostial lesion. Various modifications to this method may be required depending on the structure into which the stent is to be placed, and the needs of particular patients. The method may be used for the placement of single or multiple self-expanding or non-self-expanding stents. Although the method is exemplified using a shuttle stent delivery system and a forward break segment, methods using other methods of stent deployment, whereby an activated forward or posterior break segment is used to stably and accurately position the stent, are readily apparent to the skilled artisan.
- the vessel or similar structure for stenting may be identified, and a path for the ostial shuttle stent delivery system may be established.
- a guiding catheter and a guide wire may be inserted to provide the proper path. The remainder of this exemplary description relates to the use of such a guiding catheter and guide wire, but the invention is not to be limited to such embodiments.
- the guiding catheter should have an internal diameter large enough to accommodate the ancillary means for expansion (e.g., a balloon catheter) and the ostial shuttle stent delivery system; for example, and not by way of limitation, where a stent is to be placed in an ostial lesion of a coronary artery, an 8, 9 or 10 French external diameter guiding catheter and a guide wire having a .014" or .018" diameter may be used.
- ancillary means for expansion e.g., a balloon catheter
- ostial shuttle stent delivery system for example, and not by way of limitation, where a stent is to be placed in an ostial lesion of a coronary artery, an 8, 9 or 10 French external diameter guiding catheter and a guide wire having a .014" or .018" diameter may be used.
- an ostial shuttle stent delivery system with at least one expandable stent mechanically or by other means attached onto the ostial deployment segment in contracted condition may be loaded, in retrograde fashion coaxially over the shaft of an ancillary means of expansion (e.g., a balloon catheter) outside the patient in either over-the-catheter or monorail manner.
- an ancillary means of expansion e.g., a balloon catheter
- the assembly comprising the ostial shuttle stent delivery system and the ancillary means of expansion (e.g., a balloon catheter) may be inserted into the guiding catheter over the guide wire.
- the ancillary means of expansion e.g., a balloon catheter
- a filter in a collapsed state, may be advanced out of the guiding catheter distal to the lesion(s) while the remainder of the shuttle is retained inside the guiding catheter by the application of traction on the proximal ends of the shuttle kept outside the patient.
- the filter may then be expanded by an intrinsic or ancillary mechanism (see supra).
- the guiding catheter containing the ostial shuttle stent delivery system and the ancillary means of expansion, may be passed, over the guide wire, into a position of the aorta proximal to the ostium of the coronary artery to be stented (see FIGURE 6).
- the ancillary means of expansion e.g., a balloon catheter
- the ancillary means of expansion may be advanced, over the guide wire, and may be positioned over the ostial lesion.
- the ancillary means of expansion may then be expanded (e.g., the balloon may be inflated) to predilate the lesion prior to stent placement (see FIGURE 7).
- the ancillary means may then be contracted (e.g., the balloon may be deflated), and then advanced to a position distal to the ostial lesion, while the ostial shuttle stent delivery system remains stationary in the guiding catheter (see FIGURE 8).
- the ancillary means may be retracted into the shuttle stent delivery system, or may be maintained in position.
- pre-dilatation may not be necessary.
- the means for expansion may be advanced distal to the ostial lesion.
- the ostial shuttle stent delivery system may then be advanced into the target vessel over the shaft of the ancillary means of expansion (e.g., the balloon catheter) (see FIGURE 9), and then the guiding catheter may be withdrawn into the parent conduit vessel, leaving the deployment segment of the shuttle stent delivery system in the target vessel.
- the guiding catheter is pulled back into the aorta (see FIGURE 10).
- the ostial deployment segment may be positioned so that its distal, stent bearing end remains in the ostium of the target vessel, but its proximal, forward break segment-bearing end is in the parent conduit vessel from which the target vessel branches.
- the ostial deployment segment may be positioned so that its distal portion remains in the coronary artery but its proximal end is in the aorta (see FIGURE 11).
- the forward break segment may then be activated (expanded), such that its transverse diameter is larger than the ostium.
- the ostial shuttle stent delivery system may then be advanced until the forward break segment stops against the wall of the parent conduit vessel from which the target vessel branches (e.g., the wall of the aorta; see FIGURE 13).
- a stent, carried on the ostial deployment segment may then be moved into the desired position within (and preferably extending over) the ostial lesion, while the position of the ancillary means of expansion (e.g., the balloon catheter) is maintained by application of traction on their proximal ends kept outside the patient. Radiopaque markers defining the location of the stent(s) may aid in stent positioning.
- the ancillary means of expansion may be withdrawn into the ostial deployment segment.
- this withdrawal may be facilitated by alterable distal tips of the shuttle stent delivery system, for example, wherein the tip is constructed of a thermal memory alloy such as nitinol, and a weak electrical current may be used to create a wider aperture to facilitate withdrawal of the ancillary means of expansion.
- the ancillary means of expansion may be expanded (e.g., the balloon may be inflated; see FIGURE 14) to deploy the stent. Note that the expanded forward break segment protects the newly deployed stent from damage or dislodgement by the guiding catheter.
- a stent is a self-expanding stent
- expansion of the deployment segment creates a structural change that releases the constrained stent; for example, central expansion may release the stent from peripherally located sleeves which overlap the edges of the stent.
- pharmaceutical substances may be released by expansion of the ostial deployment segment. Following deployment, the forward break segment may be deactivated
- the ancillary means of expansion may be contracted (e.g., the balloons may be deflated), and the ostial shuttle stent delivery system, guiding catheter, ancillary means of expansion, and guide wire, may be withdrawn from the patient.
- the guide wire may be left in the target vessel and another means of ancillary expansion (e.g., a high-pressure balloon of larger expanded diameter) or another means of assessment of stent position and geometry (e.g. intravascular ultrasound catheter) may be advanced into the treatment site and used appropriately.
Abstract
The present invention relates to a stent delivery assembly (1) to be used for stent placement in an ostial lesion. The stent delivery system includes a break segment (3a) which changes configuration to facilitate localization of the target ostium. The device includes an independently inflatable balloon (11) with a stent (6) mounted thereon.
Description
SYSTEM FOR STENT PLACEMENT IN OSTIAL LESIONS
1. INTRODUCTION The present invention relates to a stent delivery system to be used for stent placement in an ostial lesion. In particular, the stent delivery system of the invention comprises a stent delivery assembly having a break segment which changes configuration to facilitate localization of the target ostium.
2. BACKGROUND OF THE INVENTION 2.1. A HISTORY OF STENT DEVELOPMENT Over the past two decades, the fields of interventional cardiology and interventional radiology have witnessed a number of paradigm shifts in the treatment of occluded (so called "stenotic") coronary arteries (among other blood vessels, various tubular conduits and similar structures). The earliest approach, still used for particular coronary applications, is by-pass surgery, which constructs a vascular detour around the occlusion. Later, it was found that in certain patients, a much less invasive approach, which did not require thoracotomy, could be used. This technique, known as percutaneous transluminal coronary angioplasty ("PTCA"), introduces a catheter carrying a deflated balloon into a large artery in the leg or arm of a patient, threads the catheter into an occluded coronary artery, and then inflates the balloon to force open the obstruction. The balloon is then deflated, and the catheter withdrawn from the patient. PTCA has, however, two major shortcomings: first, in 3-5% of patients treated with PTCA, the treated coronary artery re-occludes within the first 24-48 hours after the procedure, despite the use of anticoagulant drugs to deter the reformation of the occlusion (called "abrupt closure"); second, in 30-50% of patients treated with PTCA, the subsequent healing process in the treated coronary artery is associated with sufficient recoil, scarring and/or proliferation of smooth muscle cells to cause re- occlusion of the artery (called "restenosis").
In hopes of preventing abrupt closure and restenosis, coronary artery stents were developed (Topol, 1994, N. Engl. J. Med. 331:539-541). Such stents are tubular devices which provide structural support for maintaining an open vessel. Recently, the placement of such stents has been found to be associated with better angiographic and clinical outcomes than PTCA (Serruys et al., 1994, N. Engl. J. Med. 331 :489-495; Fischman et al., 1994, N. Engl. J. Med. 331 :496-501), including a lower rate of restenosis. These benefits were achieved, however, at the price of significantly higher procedural costs related to intra- and post-procedural aspects of the stent procedure, and were associated with a significantly higher risk of periprocedural vascular complications, such as hemorrhage due to the aggressive anticoagulation regimen used after coronary stent placement. Modifications in the strategy of optimal stent placement ("deployment") have been introduced to minimize the risk of such complications.
Procedures used for stent deployment in a vessel generally involve the introduction of a stent, in a contracted condition, into a vessel and the optimal localization of the stent relative to the intended implantation or target site, followed by the expansion of the stent such that it is locked in the desired position in apposition to the vessel wall. Certain stents require an ancillary means for expansion. For example, a stent may be fitted over a collapsed angioplasty balloon, which is then introduced into the vessel and inflated, thereby expanding the stent and deploying it in the desired location. Such stents are referred to as "non-self-expanding stents". Other stents are capable of expanding when released from the contracted condition (similar to the release of a compressed spring); such stents are referred to as "self-expanding stents". The optimal conventional strategy for implantation of non-self- expanding stents typically incorporates three distinct steps. First, where an obstruction narrows a vessel to an extent which precludes introduction of the stent delivery system, an adequate channel for passage of the balloon-stent assembly is created by inflating a balloon not carrying a stent within the stenosed region (hereafter referred to as pre-dilatation). Second, the balloon-stent assembly is advanced into the target vessel, the collapsed stent is localized and optimally positioned relative to the intended
implantation site in the stenosis, and the stent is expanded by inflating the carrier balloon, so as to achieve contact between the stent and the walls of the vessel (deployment). In order to achieve sufficient expansion of the stent along its entire length and to anchor the stent in the target vessel, the balloon used for deployment is optimally, when inflated, of the same or slightly greater diameter than the vessel adjacent to the treatment site and of the same or greater length than the stent.
Third, optimization of the axially symmetric tubular geometry of the stent and uniform circumferential contact of the stent with the walls of the vessel is achieved by inflating a balloon capable of withstanding relatively high distending pressures within the deployed stent (hereafter referred to as post-dilatation). In order to avoid damage to the target vessel adjacent to the implanted stent, the balloon used for post-dilatation is optimally of the same length or shorter than the stent. While the first and third of these three steps may occasionally be omitted, they are recommended for most stent placement applications. For best results, the choice of balloon optimal for one of the foregoing three steps is typically not optimal for the other steps. However, when multiple balloons are used, the duration, technical difficulty and cost of the procedure increase.
2.2. SPECIAL PROBLEMS ENCOUNTERED WHEN TREATING OSTIAL LESIONS The term "ostium" derives from the Latin os, referring to the mouth.
The ostium of a vessel is located at the point of origin of the vessel. Typically, a vessel branches off from a larger parent conduit vessel. For example, the aorta gives rise to the coronary arteries; the origin of each coronary artery as it branches from the aorta is referred to as an ostium. A lesion (e.g., an atherosclerotic plaque) located at the ostium of a vessel is referred to as an "ostial lesion".
In the field of interventional cardiology, the main challenges in stenting ostial lesions in native coronary arteries, bypass grafts, renal arteries, subclavian or innominate artiers, carotid arteries and any other vessels arising from the aorta are (i) the difficulty involved in precisely localizing the ostium itself angiographically during stent delivery and implantation; (ii) the unpredictable
interactions between the guiding catheter and the stent delivery system; and (iii) optimal placement of the stent covering the ostium of the target vessel without significant length of the stent protruding into the parent vessel. The guiding catheter is optimally positioned outside the ostium but in sufficient proximity to opacity the adjacent aorta and thereby localize the target ostium. However, the guiding catheter must be maintained at a sufficient distance from the ostium to avoid dislodging or damaging the stent. Maintaining proper position of the guiding catheter and stent assembly may be further complicated by forceful blood flow through the parent vessel, e.g., the aorta.
3. SUMMARY OF THE INVENTION The present invention relates to a stent delivery system to be used in the placement of one or more stents in an ostial lesion in a patient in need of such treatment. In particular, the stent delivery system of the invention comprises a stent delivery assembly having a distally located deployment segment, wherein the deployment segment comprises a break segment which has an alterable configuration, as well as a stent-bearing segment. The break segment may be introduced into the patient in a first configuration. Then, when in proximity to the ostial lesion, the configuration of the break segment may be altered to assume a second, expanded, configuration which may be lodged against the wall of the parent conduit vessel, thereby localizing the ostium of the target vessel containing the lesion and ensuring that the stent(s) is(are) in the proper position for deployment. The dimension of the break segment in its expanded configuration orthogonal to the long axis of the target vessel is greater than the diameter of the ostium of the target vessel. One or more stents mounted, in a contracted configuration, on the deployment segment, may then be deployed by expanding the deployment segment. The configuration of the break segment may then be reversed to assume the first (unexpanded) configuration, and the entire assembly may be withdrawn from the patient.
The ostial stent delivery system of the invention may be used to avoid the complications associated with conventional methods of ostial stent placement by
enabling accurate localization of the target ostium while protecting the stent from being damaged or dislodged by, for example, a guiding catheter.
4. BRIEF DESCRIPTION OF THE FIGURES FIGURE 1. Deployment segment of ostial stent delivery system in (A) deactivated, and (b) activated, configuration.
FIGURE 2. Deployment segment of ostial shuttle showing forward break segment in (A) deactivated, and (B) activated, configuration.
FIGURE 3. Deployment segment of ostial shuttle wherein mechanism of activation of forward break segment is a balloon in (A) deactivated, and (b) activated, configuration.
FIGURE 4. Deployment segment of ostial shuttle wherein mechanism of activation of forward break segment is a nitinol wire in (A) deactivated, and (B) activated, configuration.
FIGURE 5. Deployment segment of ostial shuttle wherein mechanism of activation of forward break segment is a pair of articulated wires in (A) deactivated, and (B) activated, configuration.
FIGURE 6. Introduction of ostial shuttle, via a guiding catheter passed over a guide wire, into the proximity of the target ostial lesion.
FIGURE 7. Pre-dilatation of ostial lesion by inflation of a balloon comprised in a catheter passed over the guide wire.
FIGURE 8. Advancement of the balloon distally in the target vessel, past the ostial lesion.
FIGURE 9. Advancement of the ostial shuttle, via the guiding catheter, over the shaft of the balloon catheter, into the target vessel. FIGURE 10. Withdrawal of the guiding catheter out of the target vessel and into the aorta.
FIGURE 11. Partial withdrawal of the ostial shuttle, so that the distal portion of the ostial deployment segment remains in the target vessel but the proximal end of the ostial deployment segment is in the aorta.
FIGURE 12. Activation of the forward break segment of the ostial deployment segment.
FIGURE 13. Advancement of the ostial deployment segment until the forward break segment comes to a stop against the aortic wall. FIGURE 14. Retraction of balloon into the stent deployment segment of the ostial shuttle and stent deployment by expansion of balloon in ostial deployment segment.
FIGURE 15. Deactivation of forward break segment prior to withdrawal of assembly from patient. FIGURE 16. Release of a pharmaceutical substance upon expansion of deployment segment.
FIGURE 17. Deployment segment of ostial stent delivery system with rear break segment in (A) deactivated, and (B) activated, configuration.
FIGURE 18. Deployment segment of ostial shuttle showing rear break segment in (A) deactivated, and (b) activated, configuration.
5. DETAILED DESCRIPTION OF THE INVENTION Ostial stent delivery systems of the invention share the common feature of an ostial deployment segment having a reversibly expandable break segment located adjacent to the stent-bearing region. The break segment, when activated to an expanded configuration, allows the deployment segment to be stably and accurately positioned at the ostium of a target vessel to be stented.
Such systems may be better understood by reference to Figures 1 - 18, which illustrate nonlimiting embodiments of the invention.
FIGURE 1 depicts a deployment segment (2) of an ostial stent delivery system (1) showing forward break segment (3), optimally positioned immediately adjacent to the stent-carrying segment, in (A) deactivated (3 A) and (B) activated (3B) configuration. The ostial stent delivery system (1) includes a stent (6) crimped on a balloon (11) (prior to deployment) distal to the forward break segment.
FIGURE 2 depicts a deployment segment (2) of an ostial shuttle stent delivery system (1) showing forward break segment (3) in (A) deactivated (3C), and
(B) activated (3D), configurations. The ostial shuttle stent delivery system (1) includes a tubular catheter (4; distal region only shown), having, at its distal end, a deployment segment (2) comprising, proximal to distal, a forward break segment (3), and an expandable segment (5) on which a stent (6) is mounted. FIGURE 3 depicts a deployment segment (2) of an ostial shuttle stent delivery system ( 1 ), as in FIGURE 1 , wherein the mechanism of activation of the forward break segment (3) is a balloon, in (A) deactivated (3E) and (B) activated (3F) configurations.
FIGURE 4 depicts a deployment segment (2) of an ostial shuttle stent delivery system (1), as in FIGURE 2, wherein the mechanism of activation of the forward break segment (3) is a nitinol wire loop (7), showing the forward break segment in (A) deactivated (3G), and (B) activated (3H), configurations.
FIGURE 5 depicts a deployment segment (2) of an ostial shuttle stent delivery system (1), as in FIGURE 2 wherein the mechanism of activation of the forward break segment (3) is a pair of articulated wires (8) having articulations (20) and attached to a longitudinally placed retention wire (21), showing the forward break segment in (A) deactivated (31), and (B) activated (3J), configurations.
FIGURES 6-15 depict, schematically, a method which may be used for stent placement in an ostial lesion (9) of a target artery (10) branching off a parent conduit vessel (15). In the nonlimiting example depicted, the stent (6) is deployed by expansion of the stent-bearing portion (5) of the deployment segment of an ostial shuttle (2) by a balloon (11) comprised in a balloon catheter (12). In this specific example, an expandable, stent-bearing segment (5 A) of the deployment segment (2) is flanked by less-expandable segments (13). In FIGURE 6, a guiding catheter (16), carrying an ostial shuttle delivery system (1) and, within the tubular catheter of the shuttle (4), a balloon catheter (12), has been introduced into the proximity of the ostial lesion (9). A guide wire (14) has been passed, via the guiding catheter (16), through the parent conduit vessel (15) into an artery (10) having an ostial lesion (9).
FIGURE 7 depicts pre-dilatation of the ostial lesion (9). The balloon catheter (12) has been advanced over the guide wire (14) so that the balloon is located within the ostial lesion (9), and the balloon is inflated (11 A).
In FIGURE 8, the balloon (11) has been deflated and the balloon catheter (12) has been advanced over the guide wire (14) into the artery (10) distal to the pre-dilated ostial lesion (9).
In FIGURE 9, the ostial shuttle (1) has been advanced, out of the guiding catheter (16), over the shaft (17) of the balloon catheter (12), into the target artery (10) distal to the ostial lesion (9). In FIGURE 10, the guiding catheter (16) has been withdrawn out of the target artery (10) and into the parent conduit vessel (15). The distal end of the ostial shuttle (IB) remains in the target artery (10).
In FIGURE 11, the ostial shuttle (1) has been partially withdrawn, so that the distal portion of the ostial deployment segment (2) remains in the target artery but the proximal end of the ostial deployment segment is in the parent conduit vessel (15).
FIGURE 12 depicts activation of the forward break segment (3) of the ostial deployment segment (2). Activation is achieved, in this specific nonlimiting example, by inflating a balloon comprised in the forward break segment into activated configuration (3F).
In FIGURE 13, the ostial deployment segment (2) has been advanced until the activated forward break segment (3F) comes to a stop against the wall of the parent conduit vessel (15).
In FIGURE 14, stent deployment has been achieved by withdrawing the balloon (11) into the ostial deployment segment (2), and inflating the balloon (11 A), thereby expanding the expandable stent-bearing portion (5 A) and expanding and deploying the stent (6A). Note that the activated forward break segment (3F) prevents the guiding catheter (16), positioned in the parent conduit vessel (15), from damaging or dislodging the expanded stent (6A).
In FIGURE 15, the forward break segment has been deactivated (3E) prior to withdrawal of the guide wire (14), balloon catheter (12), guiding catheter (16), and ostial shuttle stent delivery system (1) from the patient.
FIGURE 16 illustrates, in a magnified view, the release of a pharmaceutical substance (18) represented by triangles, released by the rupture of thin-walled vesicles (19), when the deployment segment (shown in relaxed conformation in A) is expanded (B).
FIGURE 17 depicts a deployment segment (2) of an ostial stent delivery system (1) showing a osterior break segment (22) in (A) deactivated (22 A) and (B) activated (22B) configuration.
FIGURE 18 depicts a deployment segment (2) of an ostial shuttle stent delivery system (1) showing a posterior break segment (22) in (A) deactivated (22C) and (B) activated (22D) configuration.
For purposes of clarity of description, and not by way of limitation, a further detailed description of the invention is divided into the following subsections:
(i) stents;
(ii) break segments;
(iii) shuttles; and
(iv) methods of stent placement. The present invention may be used in vessels or similar conduits wherein a "parent conduit" vessel gives rise to a branch which is a smaller vessel containing an ostial lesion; this smaller vessel is referred to herein as the "target" vessel. The branching of the parent conduit vessel to give rise to the target vessel has a structure which resembles the origin of the coronary arteries from the aorta. For example, the invention may be applied to vessels such as but not limited to, bypass grafts, renal arteries, subclavian or innominate arteries, carotid arteries (or any other vessels arising from the aorta), shunts, bronchial branches, ureters, fallopian tubes, cystic and pancreatic ducts. The invention may also be applied to structures wherein a target vessel containing an ostial lesion opens into a larger space, for example, but not by way of limitation, the urethra (containing an ostial lesion) opening into the bladder.
5.1. STENTS Stents which may be delivered according to the invention include any vascular or non-vascular stent intended to be placed within a blood vessel (e.g. an artery or vein, including but not limited to a coronary artery, a carotid artery, the aorta and vena cava) or similar structure.
Vascular stents which may be used according to the invention include but are not limited to Palmaz-Schatz, Gianturco-Roubin, Cook, AVE, Strecker, Wiktor, Wallsten and Cordis stents. Stents which may be delivered according to the invention are not limited as to the design, material, length or thickness of the stent, and multiple contiguous or non-contiguous stents may be delivered.
5.2 BREAK SEGMENTS The break segment of the invention is physically associated with the device on which the stent to be deployed is mounted, so that the break segment, in activated conformation, can be lodged in the ostium, thereby stably retaining the stent in the desired position for deployment. The break segment may be located proximal to (a "forward break segment"), or alternatively, distal to (a "posterior break segment"), the mounted stent. In preferred embodiments, the stent is positioned immediately adjacent to the break segment.
The break segment may be comprised in a shuttle ostial deployment system, as described in the following section 5.3. Alternatively, the break segment may be comprised in any other device used for stent deployment known in the art. For example, where a stent is mounted on a balloon catheter for deployment, the break segment may be comprised in the balloon catheter so as to satisfy the functional criteria set forth above. FIGURE 1 depicts a balloon catheter wherein a stent is crimped onto the balloon, comprising a forward break segment in activated and deactivated configurations. FIGURE 17 depicts a similar balloon catheter/stent assembly comprising a posterior break segment in activated and deactivated configurations. In both FIGURE 1 and FIGURE 17, the break segment consists of a balloon which may be inflated to create the activated configuration and deflated so as to create the deactivated configuration.
FIGURES 2-15 and 18 relate to the use of break segments in an ostial shuttle stent delivery system (see Section 5.3, infra.).
The break segment may be fabricated from various materials, depending upon its means on activation. If the means for achieving activation is a separate activating component, such as a nitinol wire or articulated wire, the break segment may be fabricated of a base material which allows the reversible expansion of the activating component, even if the base material is not, itself, activated. In order to permit reversible expansion of such an activating component, the base material should be sufficiently expandable and elastic to permit assumption of the activated configuration and then reversion to the deactivated configuration. For example, but not by way of limitation, the base material of the break segment may be polyethylene or nylon.
Where the break segment is incorporated into a shuttle catheter, the minimum inner radial diameter of the forward break segment has the same size constraints as the shuttle catheter as a whole; namely, it must be large enough to accommodate devices that are to be passed through it. For example, where said shuttle catheter is to be used for stent placement in an ostial lesion of a coronary artery, the inner diameter should be large enough to accommodate the passage of a guide wire and the ancillary means of expansion (e.g., a balloon catheter); in nonlimiting embodiments, the inner diameter may be in the range of from 0.8 to 1.6 millimeters, and preferably from 0.9 to 1.3 millimeters.
Whether the break segment is incorporated into a shuttle catheter or another species of stent delivery system, the maximum outer diameter of the break segment, in deactivated configuration, should also conform to its intended function. For example, where the break segment is to be used in conjunction with stent placement in an ostial lesion in a coronary artery, the outer diameter of the break segment, in deactivated configuration, should be small enough to allow passage into a guiding catheter, and small enough to be safely passed into a coronary artery; in nonlimiting embodiments, the outer radial diameter may be in the range of from 1.0 to 2.0 millimeters, and preferably from 1.3 to 1.7 millimeters. When the break segment is activated (expanded), its outer radial diameter may preferably (and not by way of
limitation) be increased by 100-300 percent, and more preferably by 200 percent, in order to safely exceed the diameter of the ostium of the target vessel. For example, where the break segment is to be used in stent placement in an ostial lesion of a coronary artery, the outer diameter of the break segment, in activated configuration, may be in the range from 2.0 to 6.0 millimeters and preferably from 3.0 to 5.0 millimeters.
In one specific, nonlimiting embodiment of the invention, the break segment comprises a balloon which may be inflated to achieve an activated configuration and deflated to achieve a deactivated configuration. Such a break segment may be comprised within a balloon catheter upon which a stent may be mounted prior to deployment, as depicted in Figures 1 and 17. In such embodiments, the break segment may be activated by, for example but not by way of limitation, inflation using a separate means (e.g., a separate air conduit) from that used to inflate of the balloon catheter. Alternatively, such a break segment may be comprised in a shuttle stent delivery system, as illustrated in Figures 3 and 6-15.
In another specific, nonlimiting embodiment of the invention, the activating component is a nitinol wire comprised in the break segment. The nitinol wire is configured such that, upon passage of current through the nitinol wire, the diameter of the break segment expands. For example, the nitinol wire may be configured in a loop (see, for example, FIGURE 4) or coil positioned such that the central axis of the loop or coil is parallel with, or coincident with, the central axis of the break segment. Accordingly, the inner diameter of the loop or coil has the same minimum size constraints as the stent placement devise employed. The nitinol wire may be embedded within an elastic base material, as described above. Alternatively, the nitinol wire may on activated configuration, expand freely from the stent delivery system and in deactivated configuration, may return to its original dimensions. According to these embodiments, the ostial shuttle stent delivery system comprises a means for activating the nitinol wire by passing a current through the nitinol wire. Although a number of means of creating such current would be known to the skilled artisan, as a nonlimiting example, the current may be supplied via a battery.
In another specific, nonlimiting embodiment of the invention, the activating component may comprise an articulated wire. The articulated wire may be configured such that it may be bent at the articulation to increase the diameter of the forward break segment (for example, see FIGURE 5). Preferably, at least two such wires may be comprised in the ostial shuttle. In one specific, nonlimiting example, the articulated wire may be brought into its angular configuration by pushing its proximal end while pulling on its distal end, for example, by a retention wire (see FIGURE 5). The articulated wire may be fabricated from stainless steel, titanium, or nitinol. It may preferably have a length of 150 to 300 cm.
5.3. SHUTTLES
According to one nonlimiting series of embodiments, the invention may utilize a shuttle stent delivery system:
As described in pending United States Patent Application Serial No. 08/430,378, the entirety of which is hereby incorporated herein by reference, a "shuttle" stent delivery system provides the benefits of an optimal three-step stent placement procedure using multiple balloons but obviates the need for balloon exchanges. The system utilizes a tubular stent delivery catheter (herein referred to as a "shuttle") comprising a deployment segment having an expandable portion, onto which a stent may be mounted in a contracted conformation. The deployment segment is not expanded by means intrinsic to itself, but rather is expanded by ancillary means, for example, by a balloon catheter separate and distinct from the shuttle. Multiple balloon changes are rendered unnecessary because the structural design of the deployment segment supplies the optimal physical characteristics offered by multiple balloons. In particular embodiments of the shuttle stent delivery system, the shuttle comprises a deployment segment having an expandable portion over which a stent is mounted in contracted condition. The stent-bearing expandable portion of the deployment segment is flanked by segments which are not expandable to the same degree as the stent-bearing portion. Optionally, the deployment segment comprises a releasable biological, pharmaceutical, or structural substance.
For stent placement in a partially occluded blood vessel (or similar structure) in a patient, a guide wire, having a length greater than the balloon catheter, may be introduced into the vessel. A shuttle with an expandable stent mechanically or by other means attached onto the deployment segment in contracted condition, may be mounted coaxially over the shaft of the balloon catheter outside the patient. The shuttle may be designed to be coaxially mounted over the shaft of the balloon catheter over the entire length of the shuttle (hereafter referred to as an "over the catheter" shuttle) or only over a distal segment of the shuttle comprising the deployment segment (hereafter referred to as a "monorail" shuttle). For the over-the catheter shuttle, the balloon catheter used has a length greater than the shuttle. The balloon catheter is designed such that the balloon is reliably and repeatedly capable of advancing in unexpanded (i.e., never inflated) or collapsed (i.e., inflated at least once and then deflated) condition through the entire length of the shuttle and in and out of the distal end of the shuttle. The occluded region of the vessel may then be pre-dilated using the balloon catheter. Then, without withdrawing the balloon catheter from the patient, the balloon may be deflated and advanced beyond (distal to) the occlusion, and the shuttle, fitting over the shaft of the balloon catheter, may be positioned such that the stent-bearing deployment segment is positioned within the pre-dilated occluded portion of the vessel. The balloon may then be pulled back into the deployment segment of the shuttle, and expanded to high pressures. Expanding the balloon accomplishes deployment of the stent, and also offers the benefits of post-dilatation. The need for a separate, shorter, post-dilatation balloon should be obviated by the relatively non-expandable segments flanking the expandable region of the deployment segment, which protect the vessel adjacent to the stent from damage. Moreover, releasable substances comprised in the deployment segment may be liberated by the expansion of the deployment segment via inflation of the balloon. Following stent deployment, the balloon may be deflated and the stent delivery and balloon catheters may be removed from the patient. The shuttle stent delivery system may be used for the placement of either non-self-expanding or self-expanding stents in blood vessels or similar
structures. Moreover, the system may be used to deploy multiple stents in a single procedure, and may be used in conjunction with an anti-embolic filter.
An ostial shuttle stent delivery system, according to the invention, is a species of tubular catheter (also referred to as a "shuttle catheter") having a distal and a proximal end, wherein the proximal end may preferably be kept outside of the patient (thereby allowing the operator to adjust the position of the stent during placement) and comprising an ostial deployment segment (used for carrying and deploying the stent or stents) located at the distal end (preferably, within 2-3 cm of the distal end of the shuttle catheter). A specific example of the distal end of such a shuttle is depicted in FIGURE 2.
In one nonlimiting embodiment, the present invention relates to an ostial shuttle stent delivery system for delivering a stent in a vessel having an ostial lesion in a patient in need of such treatment, comprising a tubular catheter having, at its distal end, an ostial deployment segment comprising (a) in the proximal region of the ostial deployment segment, a forward break segment capable of reversible expansion; and (b) in the distal region of the deployment segment, an expandable portion onto which a stent is mounted.
Alternatively, the ostial shuttle stent delivery system may comprise a tubular catheter having, at its distal end, an ostial deployment segment comprising (a) in the proximal region of the ostial deployment segment, an expandable portion onto which the stent is mounted; and (b) in the distal region of the ostial deployment segment, a posterior break segment capable of reversible expansion.
The shuttle catheter may be fabricated from a variety of materials, including, but not limited to, polyethylene, nylon, and nitinol, which are the preferred materials for the placement of stents in blood vessels. The length and radial diameter of the shuttle catheter may vary depending upon the vessel or similar structure into which the stent is to be placed.
For example, but not by way of limitation, the approximate longitudinal length of the shuttle catheter for placement of a stent into a coronary artery may be in the range of from 80 to 140 centimeters, and preferably from 90 to 125 centimeters, the outer radial diameter may be in the range of from 1.0 to 2.0
millimeters, and preferably from 1.3 to 1.7 millimeters, and the inner radial diameter may be in the range of from 0.8 to 1.6 millimeters, and preferably from 0.9 to 1.3 millimeters. The radial diameters are temporarily expanded in embodiments where stent deployment is effected by an ancillary means of expansion. The ostial deployment segment of the shuttle comprises one or more expandable portions, onto which one or more stents may be mounted (e.g., compacted) prior to placement in a patient. Where the stent is to be deployed using expansion by an ancillary means, such as the inflation of a separate balloon, the stent may be mounted on an expandable segment which, in preferred embodiments of the invention, is flanked by segments (called "flanks") which are not expandable or are less expandable than the expandable portion. These less-expandable flanks protect the vessel walls adjacent to the lesion from damage during stent deployment.
For conventional stents in use for treatment of coronary arteries, the length of an expandable portion may be, for example, and not by way of limitation, in the range of from 5 to 35 millimeters, and preferably from 9 to 30 millimeters. The expandable portion and flanks may be fabricated of different materials, having different expandabilities. Alternatively, the expandable portion may be made of the same material as the remainder of the shuttle, and the flanks may be created by placing two short tubular portions of reinforcing material at the boundaries of the expandable portion, or by other means known in the art.
Markers, for example radiopaque markers such as gold, tantalum or platinum markers may be placed at the distal ends of the stent-bearing region of the shuttle, or at the location of the break segment and/or at the boundaries between an expandable portion and its flanks or between the flanks and the remainder of the shuttle to aid in stent positioning.
One or more stent(s) may be compacted onto the expandable portion or portions of the ostial deployment segment prior to placement in the patient. For non- self-expanding stents, such as, for example, a Palmaz-Schatz stent, the stent may simply be crimped onto an expandable portion of the deployment segment. For self- expanding stents, the stent may be retained in non-expanded form on the shuttle by a restraining mechanism. For example, constraining sleeves may extend over both
edges of the stent, retaining it in place until the sleeves are pulled apart by expansion of the expandable portion of the deployment segment. In the case of self-expanding or non-self expanding stents, the shuttle may optionally comprise a protective sheath which may cover the stent prior to deployment; such a sheath may be removed by retracting it by pulling on its proximal end, which may be kept outside of the patient at all times.
In certain, nonlimiting embodiments of the invention, biological, pharmaceutical, and/or structural materials may be incorporated into the ostial deployment segment of the ostial shuttle, such that these materials may be released upon expansion of the deployment segment by an ancillary means. For example, such materials may be incorporated into thin- walled vacuoles near the surface of the deployment segment closest to the wall of the vessel or similar structure into which the stent is to be placed, such that the vacuoles may rupture, releasing their contents, when the deployment segment is expanded. As another example, a biodegradable polymer layer with antithrombotic and/or antiproliferative properties may be incorporated into the ostial stent delivery catheter either over the mounted stent or between the stent and the expandable portion of the ostial deployment segment. When the deployment segment and the stent are expanded, this layer may be released from the shuttle while remaining attached to the stent in the treatment site. Materials which may be incorporated into the deployment segment include, but are not limited to, anticoagulants such as heparin, hirudin, hirulog, or platelet receptor inhibitors, thrombolytic agents such as tissue plasminogen activator, compounds that deter the proliferation of vascular smooth muscle cells (thereby decreasing the likelihood of restenosis) such as radioactive compounds, anti-CD41 antibodies or antisense oligo- deoxynucleotides, radiopaque materials such as iodine or barium salts, structural materials such as fibrin layers, endothelial cells, segments of veins or arteries or synthetic grafts such as dacron. It should be noted that incorporation of such materials into the deployment segment, with consequent local release at the site of stent placement, may decrease or eliminate the need for systemic administration of such agents or other adjunct therapies. For example, the need for aggressive systemic anti-
coagulation may be decreased, thereby diminishing the likelihood of hemorrhagic complications at the vascular access site.
The tip of the ostial shuttle catheter may, in nonlimiting embodiments, comprise a means for reversible expansion (such as a nitinol wire) to facilitate withdrawal of the ancillary means of expansion into the shuttle catheter for stent deployment and for removal from the patient.
In further nonlimiting embodiments of the invention, the ostial shuttle catheter may comprise, at its distal tip, a structure or structures capable of forming one or more antiembolic filters, with fenestrations large enough to permit the passage of blood or other fluid, but small enough to trap debris (such as fragments of thrombus or atherosclerotic plaque) freed during pre-dilatation or stent deployment. The filter may be capable of fitting over, for example, a balloon catheter shaft or guidewire, and may be capable of expansion by intrinsic or ancillary means. For example, an intrinsic means of expansion would include a filter constructed of a thermal memory alloy such as nitinol, which may be expanded by a weak electrical current. As an example of an ancillary means of expansion, a balloon may be used to expand the filter. In either case, the filter and distal region of the ostial shuttle catheter may desirably be constructed such that the filter may be advanced distal to the obstructed region of the vessel and expanded prior to pre-dilatation and stent deployment. The filter itself may preferably be sufficiently flexible, by virtue of the material of which it is made or its construction, to permit pull-back of the entire delivery system following stent deployment, with the filter in its expanded shape.
In a non-limiting example, an embolic filter is comprised in a separate element, wherein the filter (for example, a coiled structure) is positioned distal to the distal tip of the shuttle catheter, and is connected to a small diameter shaft running through the shuttle catheter and extending its proximal end outside of the patient, to permit manipulation by the operator (e.g. forward advancement, retention, and withdrawal).
In a specific non-limiting embodiment of the invention, such an embolic filter may have an alterable configuration; for example, the filter may be constructed of nitinol, and have a first conformation which is a straight wire. Upon the
passage of electrical current, this straight wire may assume a second conformation which is an inverted conical spiral of preset maximal diameter.
For stent placement, the ostial deployment segment of the shuttle catheter may be placed over the shaft of an ancillary means of expansion, such as a balloon catheter. This may be advantageous, as the delivery of stents may be improved (relative to placement over a guide wire) by the use of more rigid and larger diameter shafts as guiderails for advancing the ostial deployment segment assembly into the desired position. The shuttle catheter may be coaxial with the ancillary means of expansion over the entire length (termed an "over the catheter shuttle") or over the distal segment of the ostial shuttle catheter comprising the ostial deployment segment (termed a "monorail shuttle").
The shuttle ostial stent delivery system of the invention provides for an ancillary means of expanding the ostial deployment segment of the shuttle. While means of expansion other than a balloon catheter are envisioned (such as, for example, a nitinol wire, the distal segment of which is made to become a coil of a predetermined diameter when placed within the expandable deployment segment of the shuttle and when a weak electrical current is passed through such a nitinol wire) this ancillary element will be exemplified by and referred to hereafter as a balloon catheter. The balloon catheter may be fabricated from a variety of materials, including, but not limited to, polyethylene and nylon, which are the preferred materials for the placement of stents in blood vessels.
As described above with relation to the shuttle, the length and radial diameter of the balloon catheter may vary depending upon the vessel or similar structure into which the stent is to be placed. For example, the approximate length of the shaft of a balloon catheter for placement of a stent into a coronary artery may be in the range of from 80 to 140 centimeters, and preferably from 90 to 125 centimeters, and the radial diameter of the shaft portion may be in the range of from 0.8 to 1.6 millimeters, and preferably from 0.9 to 1.3 millimeters. The balloon portion of the balloon catheter may desirably be structured such that the balloon is capable of repeatedly and reliably advancing in unexpanded
condition as well as in collapsed condition through the entire length of the shuttle, and in and out of the distal ends of the shuttle. For example, in order to achieve these goals, the balloon may preferably be a non-compliant high-pressure balloon with longer tapered ends and a smaller refolded diameter. Such a balloon may have an exaggerated gradual gentle shoulder, wherein the change from the diameter of the balloon shaft adjacent to the balloon membrane (to which the balloon membrane is tethered) to the diameter of the fully expanded balloon takes place over a relatively long distance. Upon deflation, such a balloon, even if it is a high-pressure balloon, may preferably collapse with its edges re-wrapped snugly on the shaft without heaping up. Most preferably, such a balloon maintains the diameter of the collapsed balloon (which consists of the collapsed balloon membrane and tapered catheter shaft) smaller than the more proximal shaft of the catheter.
The balloon in preferably fabricated from polyethylene or nylon. In specific, nonlimiting examples, where the balloon is to be used in a delivery system for stent placement in coronary arteries, the dimensions of the balloon may be as follows. The balloon may preferably reach, in an inflated state, a diameter ranging from 2.0 to 5.0 millimeters, and more preferably from 2.5 to 4.5 millimeters, and an internal pressure of from 0 to 20 atmospheres, and more preferably from 4 to 20 atmospheres. Such a balloon may preferably have a rated burst pressure of from 12 to 20 atmospheres.
5.4. METHODS OF STENT PLACEMENT The following is a general description of a method for stent placement in a vessel having an ostial lesion. Various modifications to this method may be required depending on the structure into which the stent is to be placed, and the needs of particular patients. The method may be used for the placement of single or multiple self-expanding or non-self-expanding stents. Although the method is exemplified using a shuttle stent delivery system and a forward break segment, methods using other methods of stent deployment, whereby an activated forward or posterior break segment is used to stably and accurately position the stent, are readily apparent to the skilled artisan.
First, the vessel or similar structure for stenting may be identified, and a path for the ostial shuttle stent delivery system may be established. In various embodiments, a guiding catheter and a guide wire may be inserted to provide the proper path. The remainder of this exemplary description relates to the use of such a guiding catheter and guide wire, but the invention is not to be limited to such embodiments.
The guiding catheter should have an internal diameter large enough to accommodate the ancillary means for expansion (e.g., a balloon catheter) and the ostial shuttle stent delivery system; for example, and not by way of limitation, where a stent is to be placed in an ostial lesion of a coronary artery, an 8, 9 or 10 French external diameter guiding catheter and a guide wire having a .014" or .018" diameter may be used.
Then, an ostial shuttle stent delivery system with at least one expandable stent mechanically or by other means attached onto the ostial deployment segment in contracted condition may be loaded, in retrograde fashion coaxially over the shaft of an ancillary means of expansion (e.g., a balloon catheter) outside the patient in either over-the-catheter or monorail manner.
Next, the assembly comprising the ostial shuttle stent delivery system and the ancillary means of expansion (e.g., a balloon catheter) may be inserted into the guiding catheter over the guide wire.
Where an embolic filter or filters are to be used, a filter, in a collapsed state, may be advanced out of the guiding catheter distal to the lesion(s) while the remainder of the shuttle is retained inside the guiding catheter by the application of traction on the proximal ends of the shuttle kept outside the patient. The filter may then be expanded by an intrinsic or ancillary mechanism (see supra).
In the specific embodiment where a stent is to be placed in an ostial lesion of a coronary artery, the guiding catheter, containing the ostial shuttle stent delivery system and the ancillary means of expansion, may be passed, over the guide wire, into a position of the aorta proximal to the ostium of the coronary artery to be stented (see FIGURE 6).
Next, while the ostial shuttle stent delivery system is retained on the shaft of the ancillary means of expansion (e.g., a balloon catheter) inside the guiding catheter by application of traction on its proximal end kept outside the patient, the ancillary means of expansion (e.g., balloon) may be advanced, over the guide wire, and may be positioned over the ostial lesion. The ancillary means of expansion may then be expanded (e.g., the balloon may be inflated) to predilate the lesion prior to stent placement (see FIGURE 7).
The ancillary means may then be contracted (e.g., the balloon may be deflated), and then advanced to a position distal to the ostial lesion, while the ostial shuttle stent delivery system remains stationary in the guiding catheter (see FIGURE 8). Alternatively, the ancillary means may be retracted into the shuttle stent delivery system, or may be maintained in position.
Of note, in certain circumstances, pre-dilatation may not be necessary. In such circumstances, the means for expansion may be advanced distal to the ostial lesion.
The ostial shuttle stent delivery system may then be advanced into the target vessel over the shaft of the ancillary means of expansion (e.g., the balloon catheter) (see FIGURE 9), and then the guiding catheter may be withdrawn into the parent conduit vessel, leaving the deployment segment of the shuttle stent delivery system in the target vessel. Where the stent is to be placed in an ostial lesion of a coronary artery, the guiding catheter is pulled back into the aorta (see FIGURE 10).
Next, the ostial deployment segment may be positioned so that its distal, stent bearing end remains in the ostium of the target vessel, but its proximal, forward break segment-bearing end is in the parent conduit vessel from which the target vessel branches. For stent placement in an ostial lesion of a coronary artery, the ostial deployment segment may be positioned so that its distal portion remains in the coronary artery but its proximal end is in the aorta (see FIGURE 11).
The forward break segment may then be activated (expanded), such that its transverse diameter is larger than the ostium.
The ostial shuttle stent delivery system may then be advanced until the forward break segment stops against the wall of the parent conduit vessel from which the target vessel branches (e.g., the wall of the aorta; see FIGURE 13).
A stent, carried on the ostial deployment segment, may then be moved into the desired position within (and preferably extending over) the ostial lesion, while the position of the ancillary means of expansion (e.g., the balloon catheter) is maintained by application of traction on their proximal ends kept outside the patient. Radiopaque markers defining the location of the stent(s) may aid in stent positioning. The ancillary means of expansion may be withdrawn into the ostial deployment segment. In certain specific embodiments of the invention, this withdrawal may be facilitated by alterable distal tips of the shuttle stent delivery system, for example, wherein the tip is constructed of a thermal memory alloy such as nitinol, and a weak electrical current may be used to create a wider aperture to facilitate withdrawal of the ancillary means of expansion. Next, the ancillary means of expansion may be expanded (e.g., the balloon may be inflated; see FIGURE 14) to deploy the stent. Note that the expanded forward break segment protects the newly deployed stent from damage or dislodgement by the guiding catheter.
Where a stent is a self-expanding stent, expansion of the deployment segment creates a structural change that releases the constrained stent; for example, central expansion may release the stent from peripherally located sleeves which overlap the edges of the stent. In specific, nonlimiting embodiments of the invention, pharmaceutical substances may be released by expansion of the ostial deployment segment. Following deployment, the forward break segment may be deactivated
(and allowed to resume its unexpanded configuration), the ancillary means of expansion may be contracted (e.g., the balloons may be deflated), and the ostial shuttle stent delivery system, guiding catheter, ancillary means of expansion, and guide wire, may be withdrawn from the patient. Alternatively, the guide wire may be left in the target vessel and another means of ancillary expansion (e.g., a high-pressure balloon of larger expanded diameter) or another means of assessment of stent position
and geometry (e.g. intravascular ultrasound catheter) may be advanced into the treatment site and used appropriately.
Various publications are cited herein, which are hereby incorporated by reference in their entireties.
Claims
1. An ostial stent delivery catheter for delivery of a stent in a vessel having an ostial lesion in a patient in need of such treatment comprising a catheter having, at its distal end, an ostial deployment segment comprising (a) a break segment capable of reversible expansion; and (b) an independently expandable portion onto which a stent is mounted.
2. The catheter of claim 1, wherein the stent is a non-self-expanding stent.
3. The catheter of claim 2, wherein the stent is a Palmaz-Schatz stent.
4. A method for placing a stent in a first vessel, branching off of a parent conduit second vessel, said first vessel having an ostial lesion, in a patient in need of such treatment, comprising
(i) passing an ostial stent delivery catheter according to claim 1 into the first vessel; (ii) positioning the ostial deployment segment such that the break segment is located in the parent conduit second vessel;
(iii) activating the break segment such that it assumes an expanded configuration;
(iv) advancing the ostial stent delivery catheter until the activated break segment stops as it is pressed against the wall of the parent conduit second vessel, whereby the stent is positioned within the ostial lesion; (v) deploying the stent within the lesion; (vi) deactivating the break segment so that it is no longer in an expanded configuration; and (vii) withdrawing the ostial stent delivery catheter from the patient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU56055/98A AU5605598A (en) | 1996-12-03 | 1997-12-02 | System for stent placement in ostial lesions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/753,912 | 1996-12-03 | ||
US08/753,912 US5749890A (en) | 1996-12-03 | 1996-12-03 | Method and system for stent placement in ostial lesions |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998024503A1 true WO1998024503A1 (en) | 1998-06-11 |
Family
ID=25032670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/023165 WO1998024503A1 (en) | 1996-12-03 | 1997-12-02 | System for stent placement in ostial lesions |
Country Status (3)
Country | Link |
---|---|
US (1) | US5749890A (en) |
AU (1) | AU5605598A (en) |
WO (1) | WO1998024503A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19815296C2 (en) * | 1998-04-06 | 2000-08-03 | Christian Vallbracht | Positionable balloon catheter for balloon expansion and / or stent implantation in renal artery stenosis |
US7717953B2 (en) | 2004-10-13 | 2010-05-18 | Tryton Medical, Inc. | Delivery system for placement of prosthesis at luminal OS |
US8876884B2 (en) | 2003-04-14 | 2014-11-04 | Tryton Medical, Inc. | Prosthesis and deployment catheter for treating vascular bifurcations |
US9149373B2 (en) | 2009-07-02 | 2015-10-06 | Tryton Medical, Inc. | Method of treating vascular bifurcations |
US9707108B2 (en) | 2010-11-24 | 2017-07-18 | Tryton Medical, Inc. | Support for treating vascular bifurcations |
US9775728B2 (en) | 2003-04-14 | 2017-10-03 | Tryton Medical, Inc. | Vascular bifurcation prosthesis |
US10500077B2 (en) | 2012-04-26 | 2019-12-10 | Poseidon Medical Inc. | Support for treating vascular bifurcations |
Families Citing this family (492)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK124690D0 (en) | 1990-05-18 | 1990-05-18 | Henning Rud Andersen | FAT PROTECTION FOR IMPLEMENTATION IN THE BODY FOR REPLACEMENT OF NATURAL FLEET AND CATS FOR USE IN IMPLEMENTING A SUCH FAT PROTECTION |
US20020095164A1 (en) * | 1997-06-26 | 2002-07-18 | Andreas Bernard H. | Device and method for suturing tissue |
US5556382A (en) * | 1995-08-29 | 1996-09-17 | Scimed Life Systems, Inc. | Balloon perfusion catheter |
US6006134A (en) | 1998-04-30 | 1999-12-21 | Medtronic, Inc. | Method and device for electronically controlling the beating of a heart using venous electrical stimulation of nerve fibers |
US7238197B2 (en) * | 2000-05-30 | 2007-07-03 | Devax, Inc. | Endoprosthesis deployment system for treating vascular bifurcations |
US8728143B2 (en) * | 1996-06-06 | 2014-05-20 | Biosensors International Group, Ltd. | Endoprosthesis deployment system for treating vascular bifurcations |
US7686846B2 (en) * | 1996-06-06 | 2010-03-30 | Devax, Inc. | Bifurcation stent and method of positioning in a body lumen |
US6599316B2 (en) | 1996-11-04 | 2003-07-29 | Advanced Stent Technologies, Inc. | Extendible stent apparatus |
US6325826B1 (en) * | 1998-01-14 | 2001-12-04 | Advanced Stent Technologies, Inc. | Extendible stent apparatus |
US6835203B1 (en) | 1996-11-04 | 2004-12-28 | Advanced Stent Technologies, Inc. | Extendible stent apparatus |
AU4896797A (en) * | 1996-11-04 | 1998-05-29 | Davidson, Charles | Extendible stent apparatus and method for deploying the same |
US7341598B2 (en) * | 1999-01-13 | 2008-03-11 | Boston Scientific Scimed, Inc. | Stent with protruding branch portion for bifurcated vessels |
EP0850607A1 (en) | 1996-12-31 | 1998-07-01 | Cordis Corporation | Valve prosthesis for implantation in body channels |
DE69830340T2 (en) | 1997-02-03 | 2005-11-17 | Angioguard, Inc. | vascular filters |
US6096073A (en) * | 1997-02-25 | 2000-08-01 | Scimed Life Systems, Inc. | Method of deploying a stent at a lesion site located at a bifurcation in a parent vessel |
US6409755B1 (en) | 1997-05-29 | 2002-06-25 | Scimed Life Systems, Inc. | Balloon expandable stent with a self-expanding portion |
US6231516B1 (en) * | 1997-10-14 | 2001-05-15 | Vacusense, Inc. | Endoluminal implant with therapeutic and diagnostic capability |
AU2225999A (en) * | 1998-01-16 | 1999-08-02 | Emory University | Catheter and method of ostial stent placement |
US5984946A (en) * | 1998-02-27 | 1999-11-16 | Gupta; Mukesh | Diagnostic and guiding catheter |
US6099497A (en) * | 1998-03-05 | 2000-08-08 | Scimed Life Systems, Inc. | Dilatation and stent delivery system for bifurcation lesions |
JP2002507930A (en) * | 1998-04-27 | 2002-03-12 | ドゥブルル,ウィリアム,アール | Expandable support device with disease inhibitor and method of using same |
US20100036481A1 (en) * | 1998-04-27 | 2010-02-11 | Artemis Medical, Inc. | Cardiovascular Devices and Methods |
US6450989B2 (en) * | 1998-04-27 | 2002-09-17 | Artemis Medical, Inc. | Dilating and support apparatus with disease inhibitors and methods for use |
US6168621B1 (en) | 1998-05-29 | 2001-01-02 | Scimed Life Systems, Inc. | Balloon expandable stent with a self-expanding portion |
US6740113B2 (en) * | 1998-05-29 | 2004-05-25 | Scimed Life Systems, Inc. | Balloon expandable stent with a self-expanding portion |
US6143002A (en) * | 1998-08-04 | 2000-11-07 | Scimed Life Systems, Inc. | System for delivering stents to bifurcation lesions |
JP2002523152A (en) | 1998-08-19 | 2002-07-30 | クック インコーポレイティド | Preformed wire guide |
US6514281B1 (en) | 1998-09-04 | 2003-02-04 | Scimed Life Systems, Inc. | System for delivering bifurcation stents |
US8257425B2 (en) * | 1999-01-13 | 2012-09-04 | Boston Scientific Scimed, Inc. | Stent with protruding branch portion for bifurcated vessels |
US20020138094A1 (en) * | 1999-02-12 | 2002-09-26 | Thomas Borillo | Vascular filter system |
US6991641B2 (en) * | 1999-02-12 | 2006-01-31 | Cordis Corporation | Low profile vascular filter system |
US7001400B1 (en) * | 1999-03-04 | 2006-02-21 | Abbott Laboratories | Articulating suturing device and method |
US7235087B2 (en) | 1999-03-04 | 2007-06-26 | Abbott Park | Articulating suturing device and method |
US7842048B2 (en) | 2006-08-18 | 2010-11-30 | Abbott Laboratories | Articulating suture device and method |
US20040092964A1 (en) | 1999-03-04 | 2004-05-13 | Modesitt D. Bruce | Articulating suturing device and method |
US8137364B2 (en) | 2003-09-11 | 2012-03-20 | Abbott Laboratories | Articulating suturing device and method |
US6964668B2 (en) | 1999-03-04 | 2005-11-15 | Abbott Laboratories | Articulating suturing device and method |
US6317615B1 (en) | 1999-04-19 | 2001-11-13 | Cardiac Pacemakers, Inc. | Method and system for reducing arterial restenosis in the presence of an intravascular stent |
US7229462B2 (en) * | 1999-07-30 | 2007-06-12 | Angioguard, Inc. | Vascular filter system for carotid endarterectomy |
US7229463B2 (en) * | 1999-07-30 | 2007-06-12 | Angioguard, Inc. | Vascular filter system for cardiopulmonary bypass |
US6458151B1 (en) | 1999-09-10 | 2002-10-01 | Frank S. Saltiel | Ostial stent positioning device and method |
CN1409622A (en) * | 1999-09-23 | 2003-04-09 | 先进扩张技术公司 | Bifurcation stent system and method |
US6679910B1 (en) | 1999-11-12 | 2004-01-20 | Latin American Devices Llc | Intraluminal stent |
US8579966B2 (en) | 1999-11-17 | 2013-11-12 | Medtronic Corevalve Llc | Prosthetic valve for transluminal delivery |
US8016877B2 (en) | 1999-11-17 | 2011-09-13 | Medtronic Corevalve Llc | Prosthetic valve for transluminal delivery |
US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
US6210431B1 (en) * | 1999-12-10 | 2001-04-03 | John A. Power | Ostial bifurcation lesion stenting catheter |
US8241274B2 (en) | 2000-01-19 | 2012-08-14 | Medtronic, Inc. | Method for guiding a medical device |
US7749245B2 (en) | 2000-01-27 | 2010-07-06 | Medtronic, Inc. | Cardiac valve procedure methods and devices |
WO2001060285A1 (en) * | 2000-02-15 | 2001-08-23 | Eva Corporation | Temporary stent assembly for use in a surgical procedure |
EP1263484B1 (en) * | 2000-03-15 | 2007-05-16 | OrbusNeich Medical, Inc. | Coating which promotes endothelial cell adherence |
US6454799B1 (en) | 2000-04-06 | 2002-09-24 | Edwards Lifesciences Corporation | Minimally-invasive heart valves and methods of use |
US20030139803A1 (en) * | 2000-05-30 | 2003-07-24 | Jacques Sequin | Method of stenting a vessel with stent lumenal diameter increasing distally |
CA2410971C (en) * | 2000-05-31 | 2007-12-18 | Brian K. Courtney | Embolization protection system for vascular procedures |
US8435225B2 (en) * | 2000-06-02 | 2013-05-07 | Fox Hollow Technologies, Inc. | Embolization protection system for vascular procedures |
WO2002005888A1 (en) | 2000-06-30 | 2002-01-24 | Viacor Incorporated | Intravascular filter with debris entrapment mechanism |
AU2001285078A1 (en) | 2000-08-18 | 2002-03-04 | Atritech, Inc. | Expandable implant devices for filtering blood flow from atrial appendages |
US8252034B2 (en) | 2001-01-05 | 2012-08-28 | Chambers Jeffrey W | Method of positioning a stent using rods |
US7029480B2 (en) * | 2001-01-24 | 2006-04-18 | Abott Laboratories | Device and method for suturing of internal puncture sites |
US6887227B1 (en) * | 2001-02-23 | 2005-05-03 | Coaxia, Inc. | Devices and methods for preventing distal embolization from the vertebrobasilar artery using flow reversal |
WO2002067653A2 (en) * | 2001-02-26 | 2002-09-06 | Scimed Life Systems, Inc. | Bifurcated stent and delivery system |
WO2002067816A1 (en) * | 2001-02-26 | 2002-09-06 | Scimed Life Systems, Inc. | Bifurcated stent and delivery system |
WO2002067815A1 (en) | 2001-02-26 | 2002-09-06 | Scimed Life Systems, Inc. | Bifurcated stent |
US6733525B2 (en) | 2001-03-23 | 2004-05-11 | Edwards Lifesciences Corporation | Rolled minimally-invasive heart valves and methods of use |
US7556646B2 (en) | 2001-09-13 | 2009-07-07 | Edwards Lifesciences Corporation | Methods and apparatuses for deploying minimally-invasive heart valves |
FR2826863B1 (en) | 2001-07-04 | 2003-09-26 | Jacques Seguin | ASSEMBLY FOR PLACING A PROSTHETIC VALVE IN A BODY CONDUIT |
AU2002327219B2 (en) * | 2001-07-06 | 2009-04-23 | Syntach Ag | Anti-arrhythmia devices and methods of use |
WO2003007797A2 (en) * | 2001-07-17 | 2003-01-30 | Kerberos Proximal Solutions | Fluid exchange system for controlled and localized irrigation and aspiration |
FR2828091B1 (en) | 2001-07-31 | 2003-11-21 | Seguin Jacques | ASSEMBLY ALLOWING THE PLACEMENT OF A PROTHETIC VALVE IN A BODY DUCT |
US7097659B2 (en) | 2001-09-07 | 2006-08-29 | Medtronic, Inc. | Fixation band for affixing a prosthetic heart valve to tissue |
US6893460B2 (en) * | 2001-10-11 | 2005-05-17 | Percutaneous Valve Technologies Inc. | Implantable prosthetic valve |
US7147656B2 (en) | 2001-12-03 | 2006-12-12 | Xtent, Inc. | Apparatus and methods for delivery of braided prostheses |
US7137993B2 (en) | 2001-12-03 | 2006-11-21 | Xtent, Inc. | Apparatus and methods for delivery of multiple distributed stents |
US7351255B2 (en) | 2001-12-03 | 2008-04-01 | Xtent, Inc. | Stent delivery apparatus and method |
US7892273B2 (en) | 2001-12-03 | 2011-02-22 | Xtent, Inc. | Custom length stent apparatus |
US6958074B2 (en) | 2002-01-07 | 2005-10-25 | Cordis Corporation | Releasable and retrievable vascular filter system |
AU2003221976A1 (en) * | 2002-04-16 | 2003-11-03 | Tyco Healthcare Group Lp | Method and apparatus for anastomosis including an expandable anchor |
US8721713B2 (en) | 2002-04-23 | 2014-05-13 | Medtronic, Inc. | System for implanting a replacement valve |
KR100893070B1 (en) * | 2002-09-19 | 2009-04-17 | 엘지전자 주식회사 | Method and apparatus for providing and receiving multicast service in a radio communication system |
DE60231843D1 (en) | 2002-11-08 | 2009-05-14 | Jacques Seguin | ENDOPROTHESIS FOR VESSEL FORKING |
US20040111143A1 (en) * | 2002-12-06 | 2004-06-10 | Fischell Robert E. | Introducer sheath for the ostial placement of a stent |
US7160309B2 (en) | 2002-12-31 | 2007-01-09 | Laveille Kao Voss | Systems for anchoring a medical device in a body lumen |
EP1605866B1 (en) * | 2003-03-03 | 2016-07-06 | Syntach AG | Electrical conduction block implant device |
WO2004078066A2 (en) | 2003-03-03 | 2004-09-16 | Sinus Rhythm Technologies, Inc. | Primary examiner |
US7399315B2 (en) | 2003-03-18 | 2008-07-15 | Edwards Lifescience Corporation | Minimally-invasive heart valve with cusp positioners |
US20040254627A1 (en) * | 2003-04-04 | 2004-12-16 | Thompson Paul J. | Stent with end adapted for flaring |
US7972372B2 (en) | 2003-04-14 | 2011-07-05 | Tryton Medical, Inc. | Kit for treating vascular bifurcations |
US7731747B2 (en) * | 2003-04-14 | 2010-06-08 | Tryton Medical, Inc. | Vascular bifurcation prosthesis with multiple thin fronds |
US7481834B2 (en) * | 2003-04-14 | 2009-01-27 | Tryton Medical, Inc. | Stent for placement at luminal os |
US7758630B2 (en) * | 2003-04-14 | 2010-07-20 | Tryton Medical, Inc. | Helical ostium support for treating vascular bifurcations |
EP1631233A2 (en) * | 2003-05-01 | 2006-03-08 | Sinus Rhythm Technologies, Inc. | Methods and devices for creating electrical block at specific targeted sites in cardia tissue |
US7947070B2 (en) | 2003-05-16 | 2011-05-24 | Boston Scientific Scimed, Inc. | Dilatation and stent delivery system and related methods |
IL156115A (en) * | 2003-05-26 | 2009-12-24 | Hadasit Med Res Service | Stent positioning system |
US7105015B2 (en) * | 2003-06-17 | 2006-09-12 | Medtronic Vascular, Inc. | Method and system for treating an ostium of a side-branch vessel |
US8298280B2 (en) | 2003-08-21 | 2012-10-30 | Boston Scientific Scimed, Inc. | Stent with protruding branch portion for bifurcated vessels |
US7462188B2 (en) | 2003-09-26 | 2008-12-09 | Abbott Laboratories | Device and method for suturing intracardiac defects |
US20050075725A1 (en) | 2003-10-02 | 2005-04-07 | Rowe Stanton J. | Implantable prosthetic valve with non-laminar flow |
ATE475448T1 (en) * | 2003-10-03 | 2010-08-15 | Medtronic Inc | EXPANDABLE GUIDE LOCK AND DEVICE |
US9579194B2 (en) | 2003-10-06 | 2017-02-28 | Medtronic ATS Medical, Inc. | Anchoring structure with concave landing zone |
WO2005039689A2 (en) * | 2003-10-24 | 2005-05-06 | Sinus Rhythm Technologies, Inc. | Methods and devices for creating cardiac electrical blocks |
WO2005041810A2 (en) * | 2003-11-03 | 2005-05-12 | B-Balloon Ltd. | Treatment of vascular bifurcations |
US20050101968A1 (en) * | 2003-11-12 | 2005-05-12 | Dadourian Daniel G. | Ostial locator device and methods for transluminal interventions |
SE526861C2 (en) | 2003-11-17 | 2005-11-15 | Syntach Ag | Tissue lesion creation device and a set of devices for the treatment of cardiac arrhythmia disorders |
US7959666B2 (en) | 2003-12-23 | 2011-06-14 | Sadra Medical, Inc. | Methods and apparatus for endovascularly replacing a heart valve |
US7780725B2 (en) | 2004-06-16 | 2010-08-24 | Sadra Medical, Inc. | Everting heart valve |
US7381219B2 (en) | 2003-12-23 | 2008-06-03 | Sadra Medical, Inc. | Low profile heart valve and delivery system |
US8840663B2 (en) | 2003-12-23 | 2014-09-23 | Sadra Medical, Inc. | Repositionable heart valve method |
US9526609B2 (en) | 2003-12-23 | 2016-12-27 | Boston Scientific Scimed, Inc. | Methods and apparatus for endovascularly replacing a patient's heart valve |
US8603160B2 (en) | 2003-12-23 | 2013-12-10 | Sadra Medical, Inc. | Method of using a retrievable heart valve anchor with a sheath |
US11278398B2 (en) | 2003-12-23 | 2022-03-22 | Boston Scientific Scimed, Inc. | Methods and apparatus for endovascular heart valve replacement comprising tissue grasping elements |
US7326236B2 (en) | 2003-12-23 | 2008-02-05 | Xtent, Inc. | Devices and methods for controlling and indicating the length of an interventional element |
US20050137687A1 (en) | 2003-12-23 | 2005-06-23 | Sadra Medical | Heart valve anchor and method |
CN100589779C (en) | 2003-12-23 | 2010-02-17 | 萨德拉医学公司 | Repositionable heart valve |
US8828078B2 (en) | 2003-12-23 | 2014-09-09 | Sadra Medical, Inc. | Methods and apparatus for endovascular heart valve replacement comprising tissue grasping elements |
US8182528B2 (en) | 2003-12-23 | 2012-05-22 | Sadra Medical, Inc. | Locking heart valve anchor |
US20050137694A1 (en) | 2003-12-23 | 2005-06-23 | Haug Ulrich R. | Methods and apparatus for endovascularly replacing a patient's heart valve |
US20120041550A1 (en) | 2003-12-23 | 2012-02-16 | Sadra Medical, Inc. | Methods and Apparatus for Endovascular Heart Valve Replacement Comprising Tissue Grasping Elements |
US8343213B2 (en) | 2003-12-23 | 2013-01-01 | Sadra Medical, Inc. | Leaflet engagement elements and methods for use thereof |
US9005273B2 (en) | 2003-12-23 | 2015-04-14 | Sadra Medical, Inc. | Assessing the location and performance of replacement heart valves |
US8579962B2 (en) | 2003-12-23 | 2013-11-12 | Sadra Medical, Inc. | Methods and apparatus for performing valvuloplasty |
US7329279B2 (en) | 2003-12-23 | 2008-02-12 | Sadra Medical, Inc. | Methods and apparatus for endovascularly replacing a patient's heart valve |
US7445631B2 (en) | 2003-12-23 | 2008-11-04 | Sadra Medical, Inc. | Methods and apparatus for endovascularly replacing a patient's heart valve |
US7449024B2 (en) | 2003-12-23 | 2008-11-11 | Abbott Laboratories | Suturing device with split arm and method of suturing tissue |
US20050177221A1 (en) * | 2004-02-06 | 2005-08-11 | Mustapha Jihad A. | Ostial stent |
US20070038283A1 (en) * | 2004-02-06 | 2007-02-15 | Mustapha Jihad A | Ostial stent and balloon |
US9398967B2 (en) | 2004-03-02 | 2016-07-26 | Syntach Ag | Electrical conduction block implant device |
ITTO20040135A1 (en) | 2004-03-03 | 2004-06-03 | Sorin Biomedica Cardio Spa | CARDIAC VALVE PROSTHESIS |
US8007528B2 (en) * | 2004-03-17 | 2011-08-30 | Boston Scientific Scimed, Inc. | Bifurcated stent |
US7323006B2 (en) | 2004-03-30 | 2008-01-29 | Xtent, Inc. | Rapid exchange interventional devices and methods |
CN101052359A (en) | 2004-04-23 | 2007-10-10 | 3F医疗有限公司 | Implantable prosthetic valve |
CA2559540A1 (en) * | 2004-06-08 | 2005-12-29 | Advanced Stent Technologies, Inc. | Stent with protruding branch portion for bifurcated vessels |
US8317859B2 (en) | 2004-06-28 | 2012-11-27 | J.W. Medical Systems Ltd. | Devices and methods for controlling expandable prostheses during deployment |
US20050288766A1 (en) * | 2004-06-28 | 2005-12-29 | Xtent, Inc. | Devices and methods for controlling expandable prostheses during deployment |
US7462191B2 (en) * | 2004-06-30 | 2008-12-09 | Edwards Lifesciences Pvt, Inc. | Device and method for assisting in the implantation of a prosthetic valve |
US7276078B2 (en) | 2004-06-30 | 2007-10-02 | Edwards Lifesciences Pvt | Paravalvular leak detection, sealing, and prevention |
US20060052867A1 (en) | 2004-09-07 | 2006-03-09 | Medtronic, Inc | Replacement prosthetic heart valve, system and method of implant |
US7993350B2 (en) * | 2004-10-04 | 2011-08-09 | Medtronic, Inc. | Shapeable or steerable guide sheaths and methods for making and using them |
EP1809195A4 (en) * | 2004-10-08 | 2010-01-20 | Syntach Ag | Two-stage scar generation for treating atrial fibrillation |
US20060085058A1 (en) * | 2004-10-20 | 2006-04-20 | Rosenthal Arthur L | System and method for delivering a biologically active material to a body lumen |
US8562672B2 (en) | 2004-11-19 | 2013-10-22 | Medtronic, Inc. | Apparatus for treatment of cardiac valves and method of its manufacture |
US9427340B2 (en) * | 2004-12-14 | 2016-08-30 | Boston Scientific Scimed, Inc. | Stent with protruding branch portion for bifurcated vessels |
DE102005003632A1 (en) | 2005-01-20 | 2006-08-17 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Catheter for the transvascular implantation of heart valve prostheses |
US20080015569A1 (en) | 2005-02-02 | 2008-01-17 | Voyage Medical, Inc. | Methods and apparatus for treatment of atrial fibrillation |
US9510732B2 (en) | 2005-10-25 | 2016-12-06 | Intuitive Surgical Operations, Inc. | Methods and apparatus for efficient purging |
US10064540B2 (en) | 2005-02-02 | 2018-09-04 | Intuitive Surgical Operations, Inc. | Visualization apparatus for transseptal access |
US8078266B2 (en) | 2005-10-25 | 2011-12-13 | Voyage Medical, Inc. | Flow reduction hood systems |
US11478152B2 (en) | 2005-02-02 | 2022-10-25 | Intuitive Surgical Operations, Inc. | Electrophysiology mapping and visualization system |
US20080009747A1 (en) * | 2005-02-02 | 2008-01-10 | Voyage Medical, Inc. | Transmural subsurface interrogation and ablation |
US8137333B2 (en) * | 2005-10-25 | 2012-03-20 | Voyage Medical, Inc. | Delivery of biological compounds to ischemic and/or infarcted tissue |
US8050746B2 (en) | 2005-02-02 | 2011-11-01 | Voyage Medical, Inc. | Tissue visualization device and method variations |
US8934962B2 (en) | 2005-02-02 | 2015-01-13 | Intuitive Surgical Operations, Inc. | Electrophysiology mapping and visualization system |
BRPI0608179A2 (en) * | 2005-02-08 | 2009-11-17 | B Balloon Ltd | device and methods for the treatment of vascular bifurcations |
ITTO20050074A1 (en) | 2005-02-10 | 2006-08-11 | Sorin Biomedica Cardio Srl | CARDIAC VALVE PROSTHESIS |
US7331991B2 (en) * | 2005-02-25 | 2008-02-19 | California Institute Of Technology | Implantable small percutaneous valve and methods of delivery |
US7962208B2 (en) | 2005-04-25 | 2011-06-14 | Cardiac Pacemakers, Inc. | Method and apparatus for pacing during revascularization |
EP1903999B1 (en) | 2005-04-25 | 2018-11-21 | Covidien LP | Controlled fracture connections for stents |
US8702744B2 (en) * | 2005-05-09 | 2014-04-22 | Nexeon Medsystems, Inc. | Apparatus and methods for renal stenting |
US7914569B2 (en) | 2005-05-13 | 2011-03-29 | Medtronics Corevalve Llc | Heart valve prosthesis and methods of manufacture and use |
DE102005022423B3 (en) * | 2005-05-14 | 2007-01-18 | Osypka, Peter, Dr.-Ing. | Device for introducing an article inside a blood vessel or the heart |
US9034025B2 (en) * | 2005-05-23 | 2015-05-19 | Ostial Corporation | Balloon catheters and methods for use |
WO2006127825A1 (en) * | 2005-05-23 | 2006-11-30 | Incept Llc | Apparatus and methods for locating an ostium of a vessel |
US7862601B2 (en) * | 2005-05-23 | 2011-01-04 | Incept Llc | Apparatus and methods for delivering a stent into an ostium |
US8480728B2 (en) * | 2005-05-26 | 2013-07-09 | Boston Scientific Scimed, Inc. | Stent side branch deployment initiation geometry |
US20060271161A1 (en) * | 2005-05-26 | 2006-11-30 | Boston Scientific Scimed, Inc. | Selective treatment of stent side branch petals |
US8317855B2 (en) * | 2005-05-26 | 2012-11-27 | Boston Scientific Scimed, Inc. | Crimpable and expandable side branch cell |
WO2006127985A2 (en) * | 2005-05-26 | 2006-11-30 | Texas Heart Institute | Surgical system and method for attaching a prosthetic vessel to a hollow structure |
US7780723B2 (en) | 2005-06-13 | 2010-08-24 | Edwards Lifesciences Corporation | Heart valve delivery system |
US8267947B2 (en) | 2005-08-08 | 2012-09-18 | Abbott Laboratories | Vascular suturing device |
US8083754B2 (en) | 2005-08-08 | 2011-12-27 | Abbott Laboratories | Vascular suturing device with needle capture |
US7883517B2 (en) | 2005-08-08 | 2011-02-08 | Abbott Laboratories | Vascular suturing device |
US7582111B2 (en) * | 2005-08-22 | 2009-09-01 | Incept, Llc | Steep-taper flared stents and apparatus and methods for delivering them |
US8920442B2 (en) | 2005-08-24 | 2014-12-30 | Abbott Vascular Inc. | Vascular opening edge eversion methods and apparatuses |
US9456811B2 (en) | 2005-08-24 | 2016-10-04 | Abbott Vascular Inc. | Vascular closure methods and apparatuses |
US20070060895A1 (en) | 2005-08-24 | 2007-03-15 | Sibbitt Wilmer L Jr | Vascular closure methods and apparatuses |
US8038706B2 (en) * | 2005-09-08 | 2011-10-18 | Boston Scientific Scimed, Inc. | Crown stent assembly |
US8043366B2 (en) | 2005-09-08 | 2011-10-25 | Boston Scientific Scimed, Inc. | Overlapping stent |
US7731741B2 (en) | 2005-09-08 | 2010-06-08 | Boston Scientific Scimed, Inc. | Inflatable bifurcation stent |
CA2623254A1 (en) * | 2005-09-21 | 2007-03-29 | B-Balloon Ltd. | Bifurcated balloon and stent |
US20070078510A1 (en) | 2005-09-26 | 2007-04-05 | Ryan Timothy R | Prosthetic cardiac and venous valves |
US20070173918A1 (en) * | 2005-09-30 | 2007-07-26 | Dreher James H | Apparatus and methods for locating an ostium of a vessel |
US8167932B2 (en) | 2005-10-18 | 2012-05-01 | Edwards Lifesciences Corporation | Heart valve delivery system with valve catheter |
US8545530B2 (en) * | 2005-10-19 | 2013-10-01 | Pulsar Vascular, Inc. | Implantable aneurysm closure systems and methods |
CA2625826C (en) | 2005-10-19 | 2014-08-05 | Pulsar Vascular, Inc. | Methods and systems for endovascularly clipping and repairing lumen and tissue defects |
US8221310B2 (en) | 2005-10-25 | 2012-07-17 | Voyage Medical, Inc. | Tissue visualization device and method variations |
WO2007051183A1 (en) * | 2005-10-28 | 2007-05-03 | Incept, Llc | Flared stents and apparatus and methods for delivering them |
US20070100279A1 (en) * | 2005-11-03 | 2007-05-03 | Paragon Intellectual Properties, Llc | Radiopaque-balloon microcatheter and methods of manufacture |
US20070112418A1 (en) | 2005-11-14 | 2007-05-17 | Boston Scientific Scimed, Inc. | Stent with spiral side-branch support designs |
ES2425948T3 (en) * | 2005-11-14 | 2013-10-18 | Covidien Lp | Cannula delivery system for ostial sites within a duct |
US7766893B2 (en) * | 2005-12-07 | 2010-08-03 | Boston Scientific Scimed, Inc. | Tapered multi-chamber balloon |
US8343211B2 (en) | 2005-12-14 | 2013-01-01 | Boston Scientific Scimed, Inc. | Connectors for bifurcated stent |
US8435284B2 (en) | 2005-12-14 | 2013-05-07 | Boston Scientific Scimed, Inc. | Telescoping bifurcated stent |
US7540881B2 (en) | 2005-12-22 | 2009-06-02 | Boston Scientific Scimed, Inc. | Bifurcation stent pattern |
US20070213813A1 (en) | 2005-12-22 | 2007-09-13 | Symetis Sa | Stent-valves for valve replacement and associated methods and systems for surgery |
US9078781B2 (en) | 2006-01-11 | 2015-07-14 | Medtronic, Inc. | Sterile cover for compressible stents used in percutaneous device delivery systems |
EP1988851A2 (en) | 2006-02-14 | 2008-11-12 | Sadra Medical, Inc. | Systems and methods for delivering a medical implant |
US20080275550A1 (en) * | 2006-02-24 | 2008-11-06 | Arash Kheradvar | Implantable small percutaneous valve and methods of delivery |
US7780724B2 (en) * | 2006-02-24 | 2010-08-24 | California Institute Of Technology | Monolithic in situ forming valve system |
US20070208414A1 (en) * | 2006-03-06 | 2007-09-06 | Shawn Sorenson | Tapered strength rings on a bifurcated stent petal |
US20070208419A1 (en) * | 2006-03-06 | 2007-09-06 | Boston Scientific Scimed, Inc. | Bifurcation stent with uniform side branch projection |
US7833264B2 (en) * | 2006-03-06 | 2010-11-16 | Boston Scientific Scimed, Inc. | Bifurcated stent |
US20070208415A1 (en) * | 2006-03-06 | 2007-09-06 | Kevin Grotheim | Bifurcated stent with controlled drug delivery |
US20070208411A1 (en) * | 2006-03-06 | 2007-09-06 | Boston Scientific Scimed, Inc. | Bifurcated stent with surface area gradient |
US8298278B2 (en) * | 2006-03-07 | 2012-10-30 | Boston Scientific Scimed, Inc. | Bifurcated stent with improvement securement |
JP2009530060A (en) | 2006-03-20 | 2009-08-27 | エックステント・インコーポレーテッド | Apparatus and method for deploying connected prosthetic segments |
US20070225788A1 (en) * | 2006-03-24 | 2007-09-27 | Fischell Robert E | Device and method for placing a stent at the ostium of a blood vessel |
US8075615B2 (en) | 2006-03-28 | 2011-12-13 | Medtronic, Inc. | Prosthetic cardiac valve formed from pericardium material and methods of making same |
US20070239254A1 (en) * | 2006-04-07 | 2007-10-11 | Chris Chia | System for percutaneous delivery and removal of a prosthetic valve |
US20070239252A1 (en) * | 2006-04-10 | 2007-10-11 | Medtronic Vascular, Inc. | A Mechanism to Ensure Placement of Ostial Renal Stents |
US20070244394A1 (en) * | 2006-04-18 | 2007-10-18 | Trevor Greenan | System and Method of Branch Vessel Marking |
US7651520B2 (en) * | 2006-05-30 | 2010-01-26 | Ostial Solutions, Llc | Means and method for the accurate placement of a stent at the ostium of an artery |
US9055906B2 (en) | 2006-06-14 | 2015-06-16 | Intuitive Surgical Operations, Inc. | In-vivo visualization systems |
EP2051673A2 (en) | 2006-06-23 | 2009-04-29 | Boston Scientific Limited | Bifurcated stent with twisted hinges |
US9585743B2 (en) | 2006-07-31 | 2017-03-07 | Edwards Lifesciences Cardiaq Llc | Surgical implant devices and methods for their manufacture and use |
US9408607B2 (en) | 2009-07-02 | 2016-08-09 | Edwards Lifesciences Cardiaq Llc | Surgical implant devices and methods for their manufacture and use |
AU2007281553B2 (en) | 2006-07-31 | 2013-09-19 | Edwards Lifesciences Cardiaq Llc | Sealable endovascular implants and methods for their use |
US8177829B2 (en) * | 2006-08-23 | 2012-05-15 | Boston Scientific Scimed, Inc. | Auxiliary balloon catheter |
US20080097476A1 (en) | 2006-09-01 | 2008-04-24 | Voyage Medical, Inc. | Precision control systems for tissue visualization and manipulation assemblies |
US10004388B2 (en) | 2006-09-01 | 2018-06-26 | Intuitive Surgical Operations, Inc. | Coronary sinus cannulation |
CA2998123C (en) | 2006-09-08 | 2021-03-02 | Edwards Lifesciences Corporation | Integrated heart valve delivery system |
US8216267B2 (en) | 2006-09-12 | 2012-07-10 | Boston Scientific Scimed, Inc. | Multilayer balloon for bifurcated stent delivery and methods of making and using the same |
US11304800B2 (en) | 2006-09-19 | 2022-04-19 | Medtronic Ventor Technologies Ltd. | Sinus-engaging valve fixation member |
US8834564B2 (en) | 2006-09-19 | 2014-09-16 | Medtronic, Inc. | Sinus-engaging valve fixation member |
US8414643B2 (en) | 2006-09-19 | 2013-04-09 | Medtronic Ventor Technologies Ltd. | Sinus-engaging valve fixation member |
WO2008040014A2 (en) * | 2006-09-28 | 2008-04-03 | Heart Leaflet Technologies, Inc. | Delivery tool for percutaneous delivery of a prosthesis |
US7951191B2 (en) * | 2006-10-10 | 2011-05-31 | Boston Scientific Scimed, Inc. | Bifurcated stent with entire circumferential petal |
EP2083901B1 (en) | 2006-10-16 | 2017-12-27 | Medtronic Ventor Technologies Ltd. | Transapical delivery system with ventriculo-arterial overflow bypass |
US10335131B2 (en) | 2006-10-23 | 2019-07-02 | Intuitive Surgical Operations, Inc. | Methods for preventing tissue migration |
US8206429B2 (en) | 2006-11-02 | 2012-06-26 | Boston Scientific Scimed, Inc. | Adjustable bifurcation catheter incorporating electroactive polymer and methods of making and using the same |
US8414611B2 (en) * | 2006-11-03 | 2013-04-09 | Boston Scientific Scimed, Inc. | Main vessel constraining side-branch access balloon |
US8398695B2 (en) * | 2006-11-03 | 2013-03-19 | Boston Scientific Scimed, Inc. | Side branch stenting system using a main vessel constraining side branch access balloon and side branching stent |
US8449593B2 (en) | 2006-11-03 | 2013-05-28 | Covidien Lp | Stent and stent delivery system for side-branch locations in a conduit |
US7842082B2 (en) * | 2006-11-16 | 2010-11-30 | Boston Scientific Scimed, Inc. | Bifurcated stent |
JP5593545B2 (en) | 2006-12-06 | 2014-09-24 | メドトロニック シーブイ ルクセンブルク エス.アー.エール.エル. | System and method for transapical delivery of a self-expanding valve secured to an annulus |
US20080183036A1 (en) | 2006-12-18 | 2008-07-31 | Voyage Medical, Inc. | Systems and methods for unobstructed visualization and ablation |
US8758229B2 (en) | 2006-12-21 | 2014-06-24 | Intuitive Surgical Operations, Inc. | Axial visualization systems |
US8131350B2 (en) | 2006-12-21 | 2012-03-06 | Voyage Medical, Inc. | Stabilization of visualization catheters |
US8236045B2 (en) | 2006-12-22 | 2012-08-07 | Edwards Lifesciences Corporation | Implantable prosthetic valve assembly and method of making the same |
US8133270B2 (en) * | 2007-01-08 | 2012-03-13 | California Institute Of Technology | In-situ formation of a valve |
US7959668B2 (en) * | 2007-01-16 | 2011-06-14 | Boston Scientific Scimed, Inc. | Bifurcated stent |
WO2008103295A2 (en) | 2007-02-16 | 2008-08-28 | Medtronic, Inc. | Replacement prosthetic heart valves and methods of implantation |
US20080199510A1 (en) | 2007-02-20 | 2008-08-21 | Xtent, Inc. | Thermo-mechanically controlled implants and methods of use |
US8544309B2 (en) | 2007-02-27 | 2013-10-01 | Mayo Foundation For Medical Education And Research | Ostial stent flaring apparatus |
US8486132B2 (en) | 2007-03-22 | 2013-07-16 | J.W. Medical Systems Ltd. | Devices and methods for controlling expandable prostheses during deployment |
US8118861B2 (en) * | 2007-03-28 | 2012-02-21 | Boston Scientific Scimed, Inc. | Bifurcation stent and balloon assemblies |
US8647376B2 (en) * | 2007-03-30 | 2014-02-11 | Boston Scientific Scimed, Inc. | Balloon fold design for deployment of bifurcated stent petal architecture |
US7896915B2 (en) | 2007-04-13 | 2011-03-01 | Jenavalve Technology, Inc. | Medical device for treating a heart valve insufficiency |
FR2915087B1 (en) | 2007-04-20 | 2021-11-26 | Corevalve Inc | IMPLANT FOR TREATMENT OF A HEART VALVE, IN PARTICULAR OF A MITRAL VALVE, EQUIPMENT INCLUDING THIS IMPLANT AND MATERIAL FOR PLACING THIS IMPLANT. |
US7776080B2 (en) * | 2007-04-25 | 2010-08-17 | Abbott Cardiovascualr Systems Inc. | Stent delivery catheter system and method of implanting a self-expanding stent with embolic protection |
EP2148608A4 (en) | 2007-04-27 | 2010-04-28 | Voyage Medical Inc | Complex shape steerable tissue visualization and manipulation catheter |
US8657805B2 (en) | 2007-05-08 | 2014-02-25 | Intuitive Surgical Operations, Inc. | Complex shape steerable tissue visualization and manipulation catheter |
EP3025636B1 (en) | 2007-05-11 | 2017-11-01 | Intuitive Surgical Operations, Inc. | Visual electrode ablation systems |
US8574244B2 (en) | 2007-06-25 | 2013-11-05 | Abbott Laboratories | System for closing a puncture in a vessel wall |
US9566178B2 (en) | 2010-06-24 | 2017-02-14 | Edwards Lifesciences Cardiaq Llc | Actively controllable stent, stent graft, heart valve and method of controlling same |
US8747458B2 (en) | 2007-08-20 | 2014-06-10 | Medtronic Ventor Technologies Ltd. | Stent loading tool and method for use thereof |
US8100820B2 (en) * | 2007-08-22 | 2012-01-24 | Edwards Lifesciences Corporation | Implantable device for treatment of ventricular dilation |
US8235985B2 (en) | 2007-08-31 | 2012-08-07 | Voyage Medical, Inc. | Visualization and ablation system variations |
US7959669B2 (en) * | 2007-09-12 | 2011-06-14 | Boston Scientific Scimed, Inc. | Bifurcated stent with open ended side branch support |
DE102007043830A1 (en) | 2007-09-13 | 2009-04-02 | Lozonschi, Lucian, Madison | Heart valve stent |
DE202008018589U1 (en) | 2007-09-26 | 2016-03-14 | St. Jude Medical, Inc. | Foldable heart valve prostheses |
US9532868B2 (en) | 2007-09-28 | 2017-01-03 | St. Jude Medical, Inc. | Collapsible-expandable prosthetic heart valves with structures for clamping native tissue |
US10856970B2 (en) | 2007-10-10 | 2020-12-08 | Medtronic Ventor Technologies Ltd. | Prosthetic heart valve for transfemoral delivery |
US9848981B2 (en) | 2007-10-12 | 2017-12-26 | Mayo Foundation For Medical Education And Research | Expandable valve prosthesis with sealing mechanism |
US7833266B2 (en) | 2007-11-28 | 2010-11-16 | Boston Scientific Scimed, Inc. | Bifurcated stent with drug wells for specific ostial, carina, and side branch treatment |
EP2227188B1 (en) * | 2007-12-03 | 2011-04-27 | Medkardia Ltd. | Stent placement system |
EP4079261A1 (en) | 2007-12-14 | 2022-10-26 | Edwards Lifesciences Corporation | Leaflet attachment frame for a prosthetic valve |
US8277501B2 (en) * | 2007-12-21 | 2012-10-02 | Boston Scientific Scimed, Inc. | Bi-stable bifurcated stent petal geometry |
WO2009088953A2 (en) | 2007-12-31 | 2009-07-16 | Boston Scientific Scimed Inc. | Bifurcation stent delivery system and methods |
US9486345B2 (en) * | 2008-01-03 | 2016-11-08 | Covidien Lp | Methods and systems for placement of a stent adjacent an ostium |
US8157852B2 (en) | 2008-01-24 | 2012-04-17 | Medtronic, Inc. | Delivery systems and methods of implantation for prosthetic heart valves |
US9393115B2 (en) | 2008-01-24 | 2016-07-19 | Medtronic, Inc. | Delivery systems and methods of implantation for prosthetic heart valves |
EP2254512B1 (en) | 2008-01-24 | 2016-01-06 | Medtronic, Inc. | Markers for prosthetic heart valves |
WO2009094197A1 (en) | 2008-01-24 | 2009-07-30 | Medtronic, Inc. | Stents for prosthetic heart valves |
JP5687070B2 (en) | 2008-01-24 | 2015-03-18 | メドトロニック,インコーポレイテッド | Stent for prosthetic heart valve |
US9149358B2 (en) | 2008-01-24 | 2015-10-06 | Medtronic, Inc. | Delivery systems for prosthetic heart valves |
US8858609B2 (en) | 2008-02-07 | 2014-10-14 | Intuitive Surgical Operations, Inc. | Stent delivery under direct visualization |
WO2011104269A1 (en) | 2008-02-26 | 2011-09-01 | Jenavalve Technology Inc. | Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient |
US9044318B2 (en) | 2008-02-26 | 2015-06-02 | Jenavalve Technology Gmbh | Stent for the positioning and anchoring of a valvular prosthesis |
WO2009108355A1 (en) | 2008-02-28 | 2009-09-03 | Medtronic, Inc. | Prosthetic heart valve systems |
US9241792B2 (en) | 2008-02-29 | 2016-01-26 | Edwards Lifesciences Corporation | Two-step heart valve implantation |
CA2961051C (en) | 2008-02-29 | 2020-01-14 | Edwards Lifesciences Corporation | Expandable member for deploying a prosthetic device |
US9101503B2 (en) | 2008-03-06 | 2015-08-11 | J.W. Medical Systems Ltd. | Apparatus having variable strut length and methods of use |
US8313525B2 (en) | 2008-03-18 | 2012-11-20 | Medtronic Ventor Technologies, Ltd. | Valve suturing and implantation procedures |
US20090240318A1 (en) * | 2008-03-19 | 2009-09-24 | Boston Scientific Scimed, Inc. | Stent expansion column, strut and connector slit design |
US8430927B2 (en) | 2008-04-08 | 2013-04-30 | Medtronic, Inc. | Multiple orifice implantable heart valve and methods of implantation |
US8696743B2 (en) | 2008-04-23 | 2014-04-15 | Medtronic, Inc. | Tissue attachment devices and methods for prosthetic heart valves |
US8312825B2 (en) | 2008-04-23 | 2012-11-20 | Medtronic, Inc. | Methods and apparatuses for assembly of a pericardial prosthetic heart valve |
US20090276040A1 (en) | 2008-05-01 | 2009-11-05 | Edwards Lifesciences Corporation | Device and method for replacing mitral valve |
US9061119B2 (en) | 2008-05-09 | 2015-06-23 | Edwards Lifesciences Corporation | Low profile delivery system for transcatheter heart valve |
EP2119417B2 (en) | 2008-05-16 | 2020-04-29 | Sorin Group Italia S.r.l. | Atraumatic prosthetic heart valve prosthesis |
US8932340B2 (en) * | 2008-05-29 | 2015-01-13 | Boston Scientific Scimed, Inc. | Bifurcated stent and delivery system |
WO2009149462A2 (en) | 2008-06-06 | 2009-12-10 | Edwards Lifesciences Corporation | Low profile transcatheter heart valve |
US8323335B2 (en) * | 2008-06-20 | 2012-12-04 | Edwards Lifesciences Corporation | Retaining mechanisms for prosthetic valves and methods for using |
US9101735B2 (en) | 2008-07-07 | 2015-08-11 | Intuitive Surgical Operations, Inc. | Catheter control systems |
WO2010008548A2 (en) | 2008-07-15 | 2010-01-21 | St. Jude Medical, Inc. | Collapsible and re-expandable prosthetic heart valve cuff designs and complementary technological applications |
US8652202B2 (en) | 2008-08-22 | 2014-02-18 | Edwards Lifesciences Corporation | Prosthetic heart valve and delivery apparatus |
US8388650B2 (en) | 2008-09-05 | 2013-03-05 | Pulsar Vascular, Inc. | Systems and methods for supporting or occluding a physiological opening or cavity |
EP2358307B1 (en) | 2008-09-15 | 2021-12-15 | Medtronic Ventor Technologies Ltd. | Prosthetic heart valve having identifiers for aiding in radiographic positioning |
US8721714B2 (en) | 2008-09-17 | 2014-05-13 | Medtronic Corevalve Llc | Delivery system for deployment of medical devices |
US8690936B2 (en) | 2008-10-10 | 2014-04-08 | Edwards Lifesciences Corporation | Expandable sheath for introducing an endovascular delivery device into a body |
US8894643B2 (en) * | 2008-10-10 | 2014-11-25 | Intuitive Surgical Operations, Inc. | Integral electrode placement and connection systems |
US8333012B2 (en) * | 2008-10-10 | 2012-12-18 | Voyage Medical, Inc. | Method of forming electrode placement and connection systems |
CN102245256B (en) | 2008-10-10 | 2014-07-23 | 萨德拉医学公司 | Medical devices and delivery systems for delivering medical devices |
US8137398B2 (en) | 2008-10-13 | 2012-03-20 | Medtronic Ventor Technologies Ltd | Prosthetic valve having tapered tip when compressed for delivery |
US8986361B2 (en) | 2008-10-17 | 2015-03-24 | Medtronic Corevalve, Inc. | Delivery system for deployment of medical devices |
US9468364B2 (en) | 2008-11-14 | 2016-10-18 | Intuitive Surgical Operations, Inc. | Intravascular catheter with hood and image processing systems |
EP2201911B1 (en) | 2008-12-23 | 2015-09-30 | Sorin Group Italia S.r.l. | Expandable prosthetic valve having anchoring appendages |
US20100204561A1 (en) * | 2009-02-11 | 2010-08-12 | Voyage Medical, Inc. | Imaging catheters having irrigation |
US20100217382A1 (en) * | 2009-02-25 | 2010-08-26 | Edwards Lifesciences | Mitral valve replacement with atrial anchoring |
US8512397B2 (en) | 2009-04-27 | 2013-08-20 | Sorin Group Italia S.R.L. | Prosthetic vascular conduit |
KR101788338B1 (en) | 2009-09-04 | 2017-10-19 | 펄사 배스큘라, 아이엔씨. | Systems and methods for enclosing an anatomical opening |
US20110071490A1 (en) * | 2009-09-18 | 2011-03-24 | Kassab Interventional Devices, Llc ("Kids") | System and procedure for placing a medical device proximate an ostial lesion using a catheter assembly |
US8808369B2 (en) | 2009-10-05 | 2014-08-19 | Mayo Foundation For Medical Education And Research | Minimally invasive aortic valve replacement |
US8449599B2 (en) | 2009-12-04 | 2013-05-28 | Edwards Lifesciences Corporation | Prosthetic valve for replacing mitral valve |
WO2011072084A2 (en) | 2009-12-08 | 2011-06-16 | Avalon Medical Ltd. | Device and system for transcatheter mitral valve replacement |
US20110144576A1 (en) * | 2009-12-14 | 2011-06-16 | Voyage Medical, Inc. | Catheter orientation control system mechanisms |
US8694071B2 (en) | 2010-02-12 | 2014-04-08 | Intuitive Surgical Operations, Inc. | Image stabilization techniques and methods |
US9226826B2 (en) | 2010-02-24 | 2016-01-05 | Medtronic, Inc. | Transcatheter valve structure and methods for valve delivery |
US8795354B2 (en) | 2010-03-05 | 2014-08-05 | Edwards Lifesciences Corporation | Low-profile heart valve and delivery system |
US8652204B2 (en) | 2010-04-01 | 2014-02-18 | Medtronic, Inc. | Transcatheter valve with torsion spring fixation and related systems and methods |
US9814522B2 (en) | 2010-04-06 | 2017-11-14 | Intuitive Surgical Operations, Inc. | Apparatus and methods for ablation efficacy |
IT1400327B1 (en) | 2010-05-21 | 2013-05-24 | Sorin Biomedica Cardio Srl | SUPPORT DEVICE FOR VALVULAR PROSTHESIS AND CORRESPONDING CORRESPONDENT. |
JP2013526388A (en) | 2010-05-25 | 2013-06-24 | イエナバルブ テクノロジー インク | Artificial heart valve, and transcatheter delivery prosthesis comprising an artificial heart valve and a stent |
JP5848345B2 (en) | 2010-07-09 | 2016-01-27 | ハイライフ エスエーエス | Transcatheter atrioventricular valve prosthesis |
WO2012012761A2 (en) | 2010-07-23 | 2012-01-26 | Edwards Lifesciences Corporation | Retaining mechanisms for prosthetic valves |
US9370353B2 (en) | 2010-09-01 | 2016-06-21 | Abbott Cardiovascular Systems, Inc. | Suturing devices and methods |
US9918833B2 (en) | 2010-09-01 | 2018-03-20 | Medtronic Vascular Galway | Prosthetic valve support structure |
US8663252B2 (en) | 2010-09-01 | 2014-03-04 | Abbott Cardiovascular Systems, Inc. | Suturing devices and methods |
CN106073946B (en) | 2010-09-10 | 2022-01-04 | 西美蒂斯股份公司 | Valve replacement device, delivery device for a valve replacement device and method of producing a valve replacement device |
US20120078340A1 (en) * | 2010-09-29 | 2012-03-29 | Gupta Manish P | Stent positioning and deployment assembly and method for treating a side-branch vessel |
DE202011111128U1 (en) | 2010-10-05 | 2020-05-27 | Edwards Lifesciences Corporation | Prosthetic heart valve |
CN105380730B (en) | 2010-10-05 | 2018-08-17 | 爱德华兹生命科学公司 | Heart valve prosthesis |
EP2486893B1 (en) | 2011-02-14 | 2017-07-05 | Sorin Group Italia S.r.l. | Sutureless anchoring device for cardiac valve prostheses |
EP2486894B1 (en) | 2011-02-14 | 2021-06-09 | Sorin Group Italia S.r.l. | Sutureless anchoring device for cardiac valve prostheses |
US9155619B2 (en) | 2011-02-25 | 2015-10-13 | Edwards Lifesciences Corporation | Prosthetic heart valve delivery apparatus |
US9586024B2 (en) | 2011-04-18 | 2017-03-07 | Medtronic Vascular, Inc. | Guide catheter with radiopaque filaments for locating an ostium |
EP2520251A1 (en) | 2011-05-05 | 2012-11-07 | Symetis SA | Method and Apparatus for Compressing Stent-Valves |
US9289282B2 (en) | 2011-05-31 | 2016-03-22 | Edwards Lifesciences Corporation | System and method for treating valve insufficiency or vessel dilatation |
KR102019025B1 (en) | 2011-06-03 | 2019-09-06 | 펄사 배스큘라, 아이엔씨. | Systems and methods for enclosing an anatomical opening, including shock absorbing aneurysm devices |
WO2012167156A1 (en) | 2011-06-03 | 2012-12-06 | Pulsar Vascular, Inc. | Aneurysm devices with additional anchoring mechanisms and associated systems and methods |
CA2835893C (en) | 2011-07-12 | 2019-03-19 | Boston Scientific Scimed, Inc. | Coupling system for medical devices |
US8795357B2 (en) | 2011-07-15 | 2014-08-05 | Edwards Lifesciences Corporation | Perivalvular sealing for transcatheter heart valve |
US9119716B2 (en) | 2011-07-27 | 2015-09-01 | Edwards Lifesciences Corporation | Delivery systems for prosthetic heart valve |
US9668859B2 (en) | 2011-08-05 | 2017-06-06 | California Institute Of Technology | Percutaneous heart valve delivery systems |
EP4289398A3 (en) | 2011-08-11 | 2024-03-13 | Tendyne Holdings, Inc. | Improvements for prosthetic valves and related inventions |
ES2809210T3 (en) | 2011-10-05 | 2021-03-03 | Pulsar Vascular Inc | Systems and devices for wrapping an anatomical opening |
US9827093B2 (en) | 2011-10-21 | 2017-11-28 | Edwards Lifesciences Cardiaq Llc | Actively controllable stent, stent graft, heart valve and method of controlling same |
US8951243B2 (en) | 2011-12-03 | 2015-02-10 | Boston Scientific Scimed, Inc. | Medical device handle |
CA3201836A1 (en) | 2011-12-09 | 2013-06-13 | Edwards Lifesciences Corporation | Prosthetic heart valve having improved commissure supports |
CN103974676B (en) | 2011-12-09 | 2016-12-07 | 波士顿科学西美德公司 | Utilize under the inner membrance of biological absorbable support the most logical |
US9827092B2 (en) | 2011-12-16 | 2017-11-28 | Tendyne Holdings, Inc. | Tethers for prosthetic mitral valve |
EP2609893B1 (en) | 2011-12-29 | 2014-09-03 | Sorin Group Italia S.r.l. | A kit for implanting prosthetic vascular conduits |
US10172708B2 (en) | 2012-01-25 | 2019-01-08 | Boston Scientific Scimed, Inc. | Valve assembly with a bioabsorbable gasket and a replaceable valve implant |
CA2865013C (en) | 2012-02-22 | 2020-12-15 | Syntheon Cardiology, Llc | Actively controllable stent, stent graft, heart valve and method of controlling same |
US8864778B2 (en) | 2012-04-10 | 2014-10-21 | Abbott Cardiovascular Systems, Inc. | Apparatus and method for suturing body lumens |
US8858573B2 (en) | 2012-04-10 | 2014-10-14 | Abbott Cardiovascular Systems, Inc. | Apparatus and method for suturing body lumens |
JP6411331B2 (en) | 2012-05-10 | 2018-10-24 | パルサー バスキュラー インコーポレイテッド | Aneurysm device with coil |
US9241707B2 (en) | 2012-05-31 | 2016-01-26 | Abbott Cardiovascular Systems, Inc. | Systems, methods, and devices for closing holes in body lumens |
US9883941B2 (en) | 2012-06-19 | 2018-02-06 | Boston Scientific Scimed, Inc. | Replacement heart valve |
WO2014022124A1 (en) | 2012-07-28 | 2014-02-06 | Tendyne Holdings, Inc. | Improved multi-component designs for heart valve retrieval device, sealing structures and stent assembly |
US9675454B2 (en) | 2012-07-30 | 2017-06-13 | Tendyne Holdings, Inc. | Delivery systems and methods for transcatheter prosthetic valves |
US9510946B2 (en) | 2012-09-06 | 2016-12-06 | Edwards Lifesciences Corporation | Heart valve sealing devices |
ES2931210T3 (en) | 2012-11-21 | 2022-12-27 | Edwards Lifesciences Corp | Retention Mechanisms for Prosthetic Heart Valves |
US9439763B2 (en) | 2013-02-04 | 2016-09-13 | Edwards Lifesciences Corporation | Prosthetic valve for replacing mitral valve |
US9168129B2 (en) | 2013-02-12 | 2015-10-27 | Edwards Lifesciences Corporation | Artificial heart valve with scalloped frame design |
US9839543B2 (en) | 2013-03-14 | 2017-12-12 | Cook Medical Technologies Llc | Multi-stage balloon catheter |
WO2014144247A1 (en) | 2013-03-15 | 2014-09-18 | Arash Kheradvar | Handle mechanism and functionality for repositioning and retrieval of transcatheter heart valves |
US10463489B2 (en) | 2013-04-02 | 2019-11-05 | Tendyne Holdings, Inc. | Prosthetic heart valve and systems and methods for delivering the same |
US11224510B2 (en) | 2013-04-02 | 2022-01-18 | Tendyne Holdings, Inc. | Prosthetic heart valve and systems and methods for delivering the same |
US9486306B2 (en) | 2013-04-02 | 2016-11-08 | Tendyne Holdings, Inc. | Inflatable annular sealing device for prosthetic mitral valve |
US10478293B2 (en) | 2013-04-04 | 2019-11-19 | Tendyne Holdings, Inc. | Retrieval and repositioning system for prosthetic heart valve |
EP2991586A1 (en) | 2013-05-03 | 2016-03-09 | Medtronic Inc. | Valve delivery tool |
CA2908342C (en) | 2013-05-20 | 2021-11-30 | Edwards Lifesciences Corporation | Prosthetic heart valve delivery apparatus |
US9610159B2 (en) | 2013-05-30 | 2017-04-04 | Tendyne Holdings, Inc. | Structural members for prosthetic mitral valves |
JP6461122B2 (en) | 2013-06-25 | 2019-01-30 | テンダイン ホールディングス,インコーポレイテッド | Thrombus management and structural compliance features of prosthetic heart valves |
EP3027144B1 (en) | 2013-08-01 | 2017-11-08 | Tendyne Holdings, Inc. | Epicardial anchor devices |
SG10202103500PA (en) | 2013-08-12 | 2021-05-28 | Mitral Valve Tech Sarl | Apparatus and methods for implanting a replacement heart valve |
CN105491978A (en) | 2013-08-30 | 2016-04-13 | 耶拿阀门科技股份有限公司 | Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame |
WO2015058039A1 (en) | 2013-10-17 | 2015-04-23 | Robert Vidlund | Apparatus and methods for alignment and deployment of intracardiac devices |
EP3656353A1 (en) | 2013-10-28 | 2020-05-27 | Tendyne Holdings, Inc. | Prosthetic heart valve and systems for delivering the same |
US9526611B2 (en) | 2013-10-29 | 2016-12-27 | Tendyne Holdings, Inc. | Apparatus and methods for delivery of transcatheter prosthetic valves |
US9913715B2 (en) | 2013-11-06 | 2018-03-13 | St. Jude Medical, Cardiology Division, Inc. | Paravalvular leak sealing mechanism |
CR20160240A (en) | 2013-11-11 | 2016-08-04 | Edwards Lifesciences Cardiaq Llc | SYSTEMS AND METHODS FOR THE MANUFACTURE OF THE FRAME OF A CANNULA |
US9622863B2 (en) | 2013-11-22 | 2017-04-18 | Edwards Lifesciences Corporation | Aortic insufficiency repair device and method |
US10098734B2 (en) | 2013-12-05 | 2018-10-16 | Edwards Lifesciences Corporation | Prosthetic heart valve and delivery apparatus |
WO2015120122A2 (en) | 2014-02-05 | 2015-08-13 | Robert Vidlund | Apparatus and methods for transfemoral delivery of prosthetic mitral valve |
US9986993B2 (en) | 2014-02-11 | 2018-06-05 | Tendyne Holdings, Inc. | Adjustable tether and epicardial pad system for prosthetic heart valve |
AU2015229708B2 (en) | 2014-03-10 | 2019-08-15 | Tendyne Holdings, Inc. | Devices and methods for positioning and monitoring tether load for prosthetic mitral valve |
US9532870B2 (en) | 2014-06-06 | 2017-01-03 | Edwards Lifesciences Corporation | Prosthetic valve for replacing a mitral valve |
US10195026B2 (en) | 2014-07-22 | 2019-02-05 | Edwards Lifesciences Corporation | Mitral valve anchoring |
US10058424B2 (en) | 2014-08-21 | 2018-08-28 | Edwards Lifesciences Corporation | Dual-flange prosthetic valve frame |
US10016272B2 (en) | 2014-09-12 | 2018-07-10 | Mitral Valve Technologies Sarl | Mitral repair and replacement devices and methods |
US9901445B2 (en) | 2014-11-21 | 2018-02-27 | Boston Scientific Scimed, Inc. | Valve locking mechanism |
EP3242630A2 (en) | 2015-01-07 | 2017-11-15 | Tendyne Holdings, Inc. | Prosthetic mitral valves and apparatus and methods for delivery of same |
US9974946B2 (en) * | 2015-04-07 | 2018-05-22 | NeuroTronik IP Holding (Jersey) Limited | Inflatable intravascular electrode supports for neuromodulation |
WO2016115375A1 (en) | 2015-01-16 | 2016-07-21 | Boston Scientific Scimed, Inc. | Displacement based lock and release mechanism |
US9861477B2 (en) | 2015-01-26 | 2018-01-09 | Boston Scientific Scimed Inc. | Prosthetic heart valve square leaflet-leaflet stitch |
US9788942B2 (en) | 2015-02-03 | 2017-10-17 | Boston Scientific Scimed Inc. | Prosthetic heart valve having tubular seal |
WO2016126524A1 (en) | 2015-02-03 | 2016-08-11 | Boston Scientific Scimed, Inc. | Prosthetic heart valve having tubular seal |
CA2975294A1 (en) | 2015-02-05 | 2016-08-11 | Tendyne Holdings, Inc. | Expandable epicardial pads and devices and methods for delivery of same |
US10426617B2 (en) | 2015-03-06 | 2019-10-01 | Boston Scientific Scimed, Inc. | Low profile valve locking mechanism and commissure assembly |
US10285809B2 (en) | 2015-03-06 | 2019-05-14 | Boston Scientific Scimed Inc. | TAVI anchoring assist device |
US10080652B2 (en) | 2015-03-13 | 2018-09-25 | Boston Scientific Scimed, Inc. | Prosthetic heart valve having an improved tubular seal |
US10327896B2 (en) | 2015-04-10 | 2019-06-25 | Edwards Lifesciences Corporation | Expandable sheath with elastomeric cross sectional portions |
US10792471B2 (en) | 2015-04-10 | 2020-10-06 | Edwards Lifesciences Corporation | Expandable sheath |
CA2983002C (en) | 2015-04-16 | 2023-07-04 | Tendyne Holdings, Inc. | Apparatus and methods for delivery, repositioning, and retrieval of transcatheter prosthetic valves |
US10010417B2 (en) | 2015-04-16 | 2018-07-03 | Edwards Lifesciences Corporation | Low-profile prosthetic heart valve for replacing a mitral valve |
US10064718B2 (en) | 2015-04-16 | 2018-09-04 | Edwards Lifesciences Corporation | Low-profile prosthetic heart valve for replacing a mitral valve |
US10709555B2 (en) | 2015-05-01 | 2020-07-14 | Jenavalve Technology, Inc. | Device and method with reduced pacemaker rate in heart valve replacement |
US10195392B2 (en) | 2015-07-02 | 2019-02-05 | Boston Scientific Scimed, Inc. | Clip-on catheter |
WO2017004377A1 (en) | 2015-07-02 | 2017-01-05 | Boston Scientific Scimed, Inc. | Adjustable nosecone |
US10179041B2 (en) | 2015-08-12 | 2019-01-15 | Boston Scientific Scimed Icn. | Pinless release mechanism |
US10136991B2 (en) | 2015-08-12 | 2018-11-27 | Boston Scientific Scimed Inc. | Replacement heart valve implant |
US10179046B2 (en) | 2015-08-14 | 2019-01-15 | Edwards Lifesciences Corporation | Gripping and pushing device for medical instrument |
US10327894B2 (en) | 2015-09-18 | 2019-06-25 | Tendyne Holdings, Inc. | Methods for delivery of prosthetic mitral valves |
US10470876B2 (en) | 2015-11-10 | 2019-11-12 | Edwards Lifesciences Corporation | Transcatheter heart valve for replacing natural mitral valve |
US10376364B2 (en) | 2015-11-10 | 2019-08-13 | Edwards Lifesciences Corporation | Implant delivery capsule |
US10321996B2 (en) | 2015-11-11 | 2019-06-18 | Edwards Lifesciences Corporation | Prosthetic valve delivery apparatus having clutch mechanism |
ES2777609T3 (en) | 2015-12-03 | 2020-08-05 | Tendyne Holdings Inc | Framework Features for Prosthetic Mitral Valves |
CN108366859B (en) | 2015-12-28 | 2021-02-05 | 坦迪尼控股股份有限公司 | Atrial capsular bag closure for prosthetic heart valves |
US10342660B2 (en) | 2016-02-02 | 2019-07-09 | Boston Scientific Inc. | Tensioned sheathing aids |
US10179043B2 (en) | 2016-02-12 | 2019-01-15 | Edwards Lifesciences Corporation | Prosthetic heart valve having multi-level sealing member |
US11219746B2 (en) | 2016-03-21 | 2022-01-11 | Edwards Lifesciences Corporation | Multi-direction steerable handles for steering catheters |
US10799677B2 (en) | 2016-03-21 | 2020-10-13 | Edwards Lifesciences Corporation | Multi-direction steerable handles for steering catheters |
US10799676B2 (en) | 2016-03-21 | 2020-10-13 | Edwards Lifesciences Corporation | Multi-direction steerable handles for steering catheters |
CA3216740A1 (en) | 2016-03-24 | 2017-09-28 | Edwards Lifesciences Corporation | Delivery system for prosthetic heart valve |
US10470877B2 (en) | 2016-05-03 | 2019-11-12 | Tendyne Holdings, Inc. | Apparatus and methods for anterior valve leaflet management |
US10583005B2 (en) | 2016-05-13 | 2020-03-10 | Boston Scientific Scimed, Inc. | Medical device handle |
EP3454795B1 (en) | 2016-05-13 | 2023-01-11 | JenaValve Technology, Inc. | Heart valve prosthesis delivery system for delivery of heart valve prosthesis with introducer sheath and loading system |
US10201416B2 (en) | 2016-05-16 | 2019-02-12 | Boston Scientific Scimed, Inc. | Replacement heart valve implant with invertible leaflets |
EP3468480B1 (en) | 2016-06-13 | 2023-01-11 | Tendyne Holdings, Inc. | Sequential delivery of two-part prosthetic mitral valve |
WO2018005779A1 (en) | 2016-06-30 | 2018-01-04 | Tegels Zachary J | Prosthetic heart valves and apparatus and methods for delivery of same |
US11065116B2 (en) | 2016-07-12 | 2021-07-20 | Tendyne Holdings, Inc. | Apparatus and methods for trans-septal retrieval of prosthetic heart valves |
US11096781B2 (en) | 2016-08-01 | 2021-08-24 | Edwards Lifesciences Corporation | Prosthetic heart valve |
US10973631B2 (en) | 2016-11-17 | 2021-04-13 | Edwards Lifesciences Corporation | Crimping accessory device for a prosthetic valve |
US10463484B2 (en) | 2016-11-17 | 2019-11-05 | Edwards Lifesciences Corporation | Prosthetic heart valve having leaflet inflow below frame |
US10603165B2 (en) | 2016-12-06 | 2020-03-31 | Edwards Lifesciences Corporation | Mechanically expanding heart valve and delivery apparatus therefor |
US11654023B2 (en) | 2017-01-23 | 2023-05-23 | Edwards Lifesciences Corporation | Covered prosthetic heart valve |
US11013600B2 (en) | 2017-01-23 | 2021-05-25 | Edwards Lifesciences Corporation | Covered prosthetic heart valve |
US11185406B2 (en) | 2017-01-23 | 2021-11-30 | Edwards Lifesciences Corporation | Covered prosthetic heart valve |
CN110392557A (en) | 2017-01-27 | 2019-10-29 | 耶拿阀门科技股份有限公司 | Heart valve simulation |
US10426449B2 (en) | 2017-02-16 | 2019-10-01 | Abbott Cardiovascular Systems, Inc. | Articulating suturing device with improved actuation and alignment mechanisms |
IL269799B2 (en) | 2017-04-18 | 2023-10-01 | Edwards Lifesciences Corp | Heart valve sealing devices and delivery devices therefor |
US11224511B2 (en) | 2017-04-18 | 2022-01-18 | Edwards Lifesciences Corporation | Heart valve sealing devices and delivery devices therefor |
US10973634B2 (en) | 2017-04-26 | 2021-04-13 | Edwards Lifesciences Corporation | Delivery apparatus for a prosthetic heart valve |
US10959846B2 (en) | 2017-05-10 | 2021-03-30 | Edwards Lifesciences Corporation | Mitral valve spacer device |
US11135056B2 (en) | 2017-05-15 | 2021-10-05 | Edwards Lifesciences Corporation | Devices and methods of commissure formation for prosthetic heart valve |
EP3630013A4 (en) | 2017-05-22 | 2020-06-17 | Edwards Lifesciences Corporation | Valve anchor and installation method |
US20210401571A9 (en) | 2017-05-31 | 2021-12-30 | Edwards Lifesciences Corporation | Sealing member for prosthetic heart valve |
US10869759B2 (en) | 2017-06-05 | 2020-12-22 | Edwards Lifesciences Corporation | Mechanically expandable heart valve |
US11026785B2 (en) | 2017-06-05 | 2021-06-08 | Edwards Lifesciences Corporation | Mechanically expandable heart valve |
EP3634311A1 (en) | 2017-06-08 | 2020-04-15 | Boston Scientific Scimed, Inc. | Heart valve implant commissure support structure |
CA3068313A1 (en) | 2017-06-30 | 2019-01-03 | Edwards Lifesciences Corporation | Docking stations for transcatheter valves |
CN110891526A (en) | 2017-06-30 | 2020-03-17 | 爱德华兹生命科学公司 | Locking and releasing mechanism for transcatheter implantable devices |
US10857334B2 (en) | 2017-07-12 | 2020-12-08 | Edwards Lifesciences Corporation | Reduced operation force inflator |
WO2019014473A1 (en) | 2017-07-13 | 2019-01-17 | Tendyne Holdings, Inc. | Prosthetic heart valves and apparatus and methods for delivery of same |
US10918473B2 (en) | 2017-07-18 | 2021-02-16 | Edwards Lifesciences Corporation | Transcatheter heart valve storage container and crimping mechanism |
EP3661458A1 (en) | 2017-08-01 | 2020-06-10 | Boston Scientific Scimed, Inc. | Medical implant locking mechanism |
KR102617878B1 (en) | 2017-08-11 | 2023-12-22 | 에드워즈 라이프사이언시스 코포레이션 | Sealing elements for artificial heart valves |
US11083575B2 (en) | 2017-08-14 | 2021-08-10 | Edwards Lifesciences Corporation | Heart valve frame design with non-uniform struts |
US10932903B2 (en) | 2017-08-15 | 2021-03-02 | Edwards Lifesciences Corporation | Skirt assembly for implantable prosthetic valve |
EP3668449A1 (en) | 2017-08-16 | 2020-06-24 | Boston Scientific Scimed, Inc. | Replacement heart valve commissure assembly |
US10898319B2 (en) | 2017-08-17 | 2021-01-26 | Edwards Lifesciences Corporation | Sealing member for prosthetic heart valve |
US10973628B2 (en) | 2017-08-18 | 2021-04-13 | Edwards Lifesciences Corporation | Pericardial sealing member for prosthetic heart valve |
US10722353B2 (en) | 2017-08-21 | 2020-07-28 | Edwards Lifesciences Corporation | Sealing member for prosthetic heart valve |
US10806573B2 (en) | 2017-08-22 | 2020-10-20 | Edwards Lifesciences Corporation | Gear drive mechanism for heart valve delivery apparatus |
JP7291124B2 (en) | 2017-08-28 | 2023-06-14 | テンダイン ホールディングス,インコーポレイテッド | Heart valve prosthesis with tethered connections |
US11051939B2 (en) | 2017-08-31 | 2021-07-06 | Edwards Lifesciences Corporation | Active introducer sheath system |
US10973629B2 (en) | 2017-09-06 | 2021-04-13 | Edwards Lifesciences Corporation | Sealing member for prosthetic heart valve |
US11147667B2 (en) | 2017-09-08 | 2021-10-19 | Edwards Lifesciences Corporation | Sealing member for prosthetic heart valve |
CN115177404A (en) | 2017-10-18 | 2022-10-14 | 爱德华兹生命科学公司 | Catheter assembly |
US11207499B2 (en) | 2017-10-20 | 2021-12-28 | Edwards Lifesciences Corporation | Steerable catheter |
WO2019144071A1 (en) | 2018-01-19 | 2019-07-25 | Boston Scientific Scimed, Inc. | Medical device delivery system with feedback loop |
JP7055882B2 (en) | 2018-01-19 | 2022-04-18 | ボストン サイエンティフィック サイムド,インコーポレイテッド | Guidance mode indwelling sensor for transcatheter valve system |
US11147668B2 (en) | 2018-02-07 | 2021-10-19 | Boston Scientific Scimed, Inc. | Medical device delivery system with alignment feature |
US11439732B2 (en) | 2018-02-26 | 2022-09-13 | Boston Scientific Scimed, Inc. | Embedded radiopaque marker in adaptive seal |
US11318011B2 (en) | 2018-04-27 | 2022-05-03 | Edwards Lifesciences Corporation | Mechanically expandable heart valve with leaflet clamps |
US11229517B2 (en) | 2018-05-15 | 2022-01-25 | Boston Scientific Scimed, Inc. | Replacement heart valve commissure assembly |
AU2018424859B2 (en) | 2018-05-23 | 2024-04-04 | Corcym S.R.L. | A cardiac valve prosthesis |
US11844914B2 (en) | 2018-06-05 | 2023-12-19 | Edwards Lifesciences Corporation | Removable volume indicator for syringe |
US11241310B2 (en) | 2018-06-13 | 2022-02-08 | Boston Scientific Scimed, Inc. | Replacement heart valve delivery device |
US20200069913A1 (en) * | 2018-09-05 | 2020-03-05 | Boston Scientific Scimed, Inc. | Aorto ostial fluid directing device |
KR20210082188A (en) | 2018-10-19 | 2021-07-02 | 에드워즈 라이프사이언시스 코포레이션 | Artificial heart valve with non-cylindrical frame |
US11779728B2 (en) | 2018-11-01 | 2023-10-10 | Edwards Lifesciences Corporation | Introducer sheath with expandable introducer |
WO2020123486A1 (en) | 2018-12-10 | 2020-06-18 | Boston Scientific Scimed, Inc. | Medical device delivery system including a resistance member |
CN113873973B (en) | 2019-03-26 | 2023-12-22 | 爱德华兹生命科学公司 | prosthetic heart valve |
US11439504B2 (en) | 2019-05-10 | 2022-09-13 | Boston Scientific Scimed, Inc. | Replacement heart valve with improved cusp washout and reduced loading |
EP3831343B1 (en) | 2019-12-05 | 2024-01-31 | Tendyne Holdings, Inc. | Braided anchor for mitral valve |
US11648114B2 (en) | 2019-12-20 | 2023-05-16 | Tendyne Holdings, Inc. | Distally loaded sheath and loading funnel |
US11951002B2 (en) | 2020-03-30 | 2024-04-09 | Tendyne Holdings, Inc. | Apparatus and methods for valve and tether fixation |
WO2022039853A1 (en) | 2020-08-19 | 2022-02-24 | Tendyne Holdings, Inc. | Fully-transseptal apical pad with pulley for tensioning |
BR112023002487A2 (en) | 2020-08-24 | 2023-05-02 | Edwards Lifesciences Corp | BALLOON COVER FOR A DISTRIBUTION APPLIANCE FOR AN EXPANDABLE PROSTHETIC HEART VALVE |
JP2023540067A (en) | 2020-08-31 | 2023-09-21 | エドワーズ ライフサイエンシーズ コーポレイション | Systems and methods for crimping and device preparation |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5456694A (en) * | 1994-05-13 | 1995-10-10 | Stentco, Inc. | Device for delivering and deploying intraluminal devices |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5591228A (en) * | 1995-05-09 | 1997-01-07 | Edoga; John K. | Methods for treating abdominal aortic aneurysms |
-
1996
- 1996-12-03 US US08/753,912 patent/US5749890A/en not_active Expired - Lifetime
-
1997
- 1997-12-02 WO PCT/US1997/023165 patent/WO1998024503A1/en active Application Filing
- 1997-12-02 AU AU56055/98A patent/AU5605598A/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5456694A (en) * | 1994-05-13 | 1995-10-10 | Stentco, Inc. | Device for delivering and deploying intraluminal devices |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19815296C2 (en) * | 1998-04-06 | 2000-08-03 | Christian Vallbracht | Positionable balloon catheter for balloon expansion and / or stent implantation in renal artery stenosis |
US8876884B2 (en) | 2003-04-14 | 2014-11-04 | Tryton Medical, Inc. | Prosthesis and deployment catheter for treating vascular bifurcations |
US9775728B2 (en) | 2003-04-14 | 2017-10-03 | Tryton Medical, Inc. | Vascular bifurcation prosthesis |
US7717953B2 (en) | 2004-10-13 | 2010-05-18 | Tryton Medical, Inc. | Delivery system for placement of prosthesis at luminal OS |
US8926685B2 (en) | 2004-10-13 | 2015-01-06 | Tryton Medical, Inc. | Prosthesis for placement at a luminal OS |
US9149373B2 (en) | 2009-07-02 | 2015-10-06 | Tryton Medical, Inc. | Method of treating vascular bifurcations |
US9707108B2 (en) | 2010-11-24 | 2017-07-18 | Tryton Medical, Inc. | Support for treating vascular bifurcations |
US10500072B2 (en) | 2010-11-24 | 2019-12-10 | Poseidon Medical Inc. | Method of treating vascular bifurcations |
US10500077B2 (en) | 2012-04-26 | 2019-12-10 | Poseidon Medical Inc. | Support for treating vascular bifurcations |
Also Published As
Publication number | Publication date |
---|---|
US5749890A (en) | 1998-05-12 |
AU5605598A (en) | 1998-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5749890A (en) | Method and system for stent placement in ostial lesions | |
US5807398A (en) | Shuttle stent delivery catheter | |
US5669924A (en) | Y-shuttle stent assembly for bifurcating vessels and method of using the same | |
WO1997015346A9 (en) | Y-shuttle stent assembly for bifurcating vessels | |
US6629992B2 (en) | Sheath for self-expanding stent | |
US10369033B2 (en) | Delivery system and method of use for deployment of self-expandable vascular device | |
JP4156710B2 (en) | Catheter device | |
US6752825B2 (en) | Nested stent apparatus | |
US20050131526A1 (en) | Stent and balloon system for bifurcated vessels and lesions | |
US5593412A (en) | Stent delivery method and apparatus | |
US6280465B1 (en) | Apparatus and method for delivering a self-expanding stent on a guide wire | |
US7666216B2 (en) | Delivery catheter for ribbon-type prosthesis and methods of use | |
US6443979B1 (en) | Expandable stent delivery sheath and method of use | |
EP1723931B1 (en) | Extendible stent apparatus and method for deploying the same | |
US9700446B2 (en) | Stent positioning system and method | |
JPH11511361A (en) | Intraluminal prosthesis delivery method and apparatus | |
WO1998048732A1 (en) | Stent delivery system | |
JP2003521971A (en) | Method and apparatus for protecting passages in the body | |
EP1906877A1 (en) | Apparatus and methods for locating an ostium of a vessel | |
WO1997048343A1 (en) | System and method for delivering helical stents | |
US20040148000A1 (en) | Self expanding stent delivery system with balloon | |
WO1997048343A9 (en) | System and method for delivering helical stents | |
US20100241069A1 (en) | Ostial lesion stent delivery system | |
WO2008106343A1 (en) | Method and apparatus for treating stenoses at bifurcated regions | |
WO2007112064A2 (en) | Conformable vascular prosthesis delivery system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |